Loading...
Docoh

Bristol-Myers Squibb (BMY)

Document and Entity Information

Document and Entity Information9 Months Ended
Sep. 30, 2020shares
Document Period End DateSep. 30,
2020
Entity Common Stock, Shares Outstanding2,259,751,518
Entity Incorporation, State or Country CodeDE
Document Type10-Q
Document Quarterly Reporttrue
Entity File Number001-01136
Entity Registrant NameBRISTOL MYERS SQUIBB CO
Entity Address, Address Line One430 E. 29th Street, 14FL
Entity Address, City or TownNew York
Entity Address, State or ProvinceNY
Entity Address, Postal Zip Code10016
City Area Code212
Local Phone Number546-4000
Entity Central Index Key0000014272
Entity Tax Identification Number22-0790350
Entity Current Reporting StatusYes
Entity Interactive Data CurrentYes
Entity Filer CategoryLarge Accelerated Filer
Entity Common Stock, Shares Outstanding2,259,751,518
Document Period End DateSep. 30,
2020
Document Transition Reportfalse
Document Fiscal Year Focus2020
Document Fiscal Period FocusQ3
Current Fiscal Year End Date--12-31
Amendment Flagfalse
Entity Small Businessfalse
Entity Shell Companyfalse
Entity Emerging Growth Companyfalse
Common Stock $0.10 Par Value [Member]
Title of 12(b) SecurityCommon Stock, $0.10 Par Value
Trading SymbolBMY
Security Exchange NameNYSE
1.000% Notes due 2025 [Member]
Title of 12(b) Security1.000% Notes due 2025
Trading SymbolBMY25
Security Exchange NameNYSE
1.750% Notes due 2035 [Member]
Title of 12(b) Security1.750% Notes due 2035
Trading SymbolBMY35
Security Exchange NameNYSE
Bristol Myers Squibb Contingent Value Rights [Member]
Title of 12(b) SecurityBristol-Myers Squibb Contingent Value Rights
Trading SymbolBMY RT
Security Exchange NameNYSE
Celgene Contingent Value Rights [Member]
Title of 12(b) SecurityCelgene Contingent Value Rights
Trading SymbolCELG RT
Security Exchange NameNYSE

CONSOLIDATED STATEMENTS OF EARN

CONSOLIDATED STATEMENTS OF EARNINGS (UNAUDITED) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200
Cost of products sold[1]2,502 1,790 8,863 5,586
Marketing, selling and administrative1,706 1,055 4,940 3,137
Research and development2,499 1,378 7,393 4,051
Amortization of acquired intangible assets2,491 25 7,162 73
Other (income)/expense, net(915)410 (488)249
Total Expenses8,283 4,658 27,870 13,096
Earnings Before Income Taxes2,257 1,349 3,580 5,104
Provision for Income Taxes379 (17)2,548 584
Net Earnings1,878 1,366 1,032 4,520
Noncontrolling Interest6 13 20 25
Net (Loss)/Earnings Attributable to BMS $ 1,872 $ 1,353 $ 1,012 $ 4,495
Earnings Per Share, Basic $ 0.83 $ 0.83 $ 0.45 $ 2.75
Earnings Per Share, Diluted $ 0.82 $ 0.83 $ 0.44 $ 2.75
Net product sales [Member]
Total Revenues $ 10,197 $ 5,768 $ 30,555 $ 17,512
Alliance and other revenues [Member]
Total Revenues $ 343 $ 239 $ 895 $ 688
[1]Excludes amortization of acquired intangible assets

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (UNAUDITED) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Statement of Comprehensive Income [Abstract]
Net Earnings $ 1,878 $ 1,366 $ 1,032 $ 4,520
Derivatives qualifying as cash flow hedges(132)38 (121)24
Pension and postretirement benefits(4)1,116 5 1,204
Available-for-sale debt securities(2)4 7 43
Foreign currency translation(5)0 (70)28
Other Comprehensive (Loss)/Income(143)1,158 (179)1,299
Comprehensive Income1,735 2,524 853 5,819
Comprehensive Income Attributable to Noncontrolling Interest6 13 20 25
Comprehensive Income Attributable to BMS $ 1,729 $ 2,511 $ 833 $ 5,794

CONSOLIDATED BALANCE SHEETS (UN

CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($) $ in MillionsSep. 30, 2020Dec. 31, 2019
Current Assets:
Cash and cash equivalents $ 19,435 $ 12,346
Marketable debt securities1,720 3,047
Receivables8,062 7,685
Inventories1,949 4,293
Other current assets3,111 1,983
Total current assets34,277 29,354
Property, plant and equipment5,740 6,252
Goodwill20,517 22,488
Other intangible assets56,698 63,969
Deferred income taxes913 510
Marketable debt securities495 767
Other non-current assets6,896 6,604
Total Assets125,536 129,944
Current Liabilities:
Short-term debt obligations3,585 3,346
Accounts payable2,441 2,445
Other current liabilities14,438 12,513
Total Current Liabilities20,464 18,304
Deferred income taxes5,913 6,454
Long-term debt41,364 43,387
Other non-current liabilities7,565 10,101
Total Liabilities75,306 78,246
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock0 0
Common stock292 292
Capital in excess of par value of stock44,435 43,709
Accumulated other comprehensive loss(1,699)(1,520)
Retained earnings32,414 34,474
Less cost of treasury stock(25,284)(25,357)
Total Bristol-Myers Squibb Company Shareholders' Equity50,158 51,598
Noncontrolling Interest72 100
Total Equity50,230 51,698
Total Liabilities and Equity $ 125,536 $ 129,944

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Millions9 Months Ended
Sep. 30, 2020Sep. 30, 2019
Cash Flows From Operating Activities:
Net Earnings $ 1,032 $ 4,520
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Depreciation and amortization, net7,690 510
Deferred income taxes1,419 (536)
Share-based compensation608 157
Impairment charges131 183
Pension settlements and amortization34 1,683
Divestiture gains and royalties(486)(1,676)
Asset acquisition charges278 25
Equity investment (gains)/losses(724)15
Contingent consideration fair value adjustments(597)0
Other adjustments(140)(21)
Increase (Decrease) in Other Operating Assets and Liabilities, Net [Abstract]
Receivables(356)434
Inventories2,571 (7)
Accounts payable56 48
Income taxes payable(2,104)(4)
Other970 698
Net Cash Provided by Operating Activities10,382 6,029
Cash Flows From Investing Activities:
Sale and maturities of marketable debt securities4,757 2,325
Purchase of marketable debt securities(3,148)(1,642)
Capital expenditures(470)(585)
Divestiture and other proceeds550 2,226
Acquisition and other payments, net of cash acquired(421)(58)
Net Cash Provided by Investing Activities1,268 2,266
Cash Flows From Financing Activities:
Short-term debt obligations, net(264)115
Issuance of long-term debt0 18,790
Repayments of Long-term Debt(1,500)(1,256)
Repurchase of common stock(81)(300)
Dividends(3,054)(2,011)
Other265 (40)
Net Cash (Used in)/Provided by Financing Activities(4,634)15,298
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents24 (15)
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect7,040 23,578
Cash, Cash Equivalents and Restricted Cash at Beginning of Period12,820 6,911
Cash, Cash Equivalents and Restricted Cash at End of Period $ 19,860 $ 30,489

BASIS OF PRESENTATION AND RECEN

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS (Notes)9 Months Ended
Sep. 30, 2020
BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING STANDARDS [Abstract]
Basis of Presentation and Recently Issued Accounting Standards [Text Block]Basis of Consolidation Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at September 30, 2020 and December 31, 2019, the results of operations for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. All intercompany balances and transactions have been eliminated. BMS’s consolidated financial statements include the assets, liabilities, operating results and cash flows of Celgene from the date of acquisition on November 20, 2019. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document. Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS’s operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue.” Use of Estimates and Judgments Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for business combinations; impairments of intangible assets; sales rebate and return accruals; legal contingencies; and income taxes. Actual results may differ from estimates. Reclassifications Certain reclassifications were made to conform the prior period interim consolidated financial statements to the current period presentation. Recently Adopted Accounting Standards Financial Instruments - Measurement of Credit Losses In June 2016, the FASB issued amended guidance for the measurement of credit losses on financial instruments. Entities are required to use a forward-looking estimated loss model. Available-for-sale debt security credit losses will be recognized as allowances rather than a reduction in amortized cost. BMS adopted the amended guidance on a modified retrospective approach on January 1, 2020. The amended guidance did not impact BMS’s results of operations.

REVENUE RECOGNITION Revenue Rec

REVENUE RECOGNITION Revenue Recognition (Notes)9 Months Ended
Sep. 30, 2020
Revenue Recognition [Abstract]
Revenue from Contract with Customer [Text Block]REVENUE The following table summarizes the disaggregation of revenue by nature: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Net product sales $ 10,197 $ 5,768 $ 30,555 $ 17,512 Alliance revenues 184 143 452 418 Other revenues 159 96 443 270 Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200 The following table summarizes GTN adjustments: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Gross product sales $ 15,211 $ 8,884 $ 43,685 $ 25,697 GTN adjustments (a) Charge-backs and cash discounts (1,440) (927) (4,072) (2,591) Medicaid and Medicare rebates (2,146) (1,362) (5,126) (3,252) Other rebates, returns, discounts and adjustments (1,428) (827) (3,932) (2,342) Total GTN adjustments (5,014) (3,116) (13,130) (8,185) Net product sales $ 10,197 $ 5,768 $ 30,555 $ 17,512 (a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $(25) million and $91 million for the three and nine months ended September 30, 2020 and $12 million and $139 million for the three and nine months ended September 30, 2019, respectively. The following table summarizes the disaggregation of revenue by product and region: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Prioritized Brands Revlimid $ 3,027 $ — $ 8,826 $ — Eliquis 2,095 1,928 6,899 5,895 Opdivo 1,780 1,817 5,199 5,441 Orencia 826 767 2,290 2,185 Pomalyst/Imnovid 777 — 2,235 — Sprycel 544 558 1,576 1,561 Yervoy 446 353 1,211 1,104 Abraxane 342 — 950 — Empliciti 96 89 290 263 Reblozyl 96 — 159 — Inrebic 13 — 40 — Zeposia 2 — 3 — Onureg 3 — 3 — Established Brands Baraclude 100 145 343 433 Vidaza 106 — 390 — Other Brands (a) 287 350 1,036 1,318 Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200 United States $ 6,542 $ 3,472 $ 19,795 $ 10,588 Europe 2,453 1,445 7,156 4,416 Rest of the World 1,361 976 4,030 2,838 Other (b) 184 114 469 358 Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200 (a) Includes BMS and Celgene products in 2020. (b) Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

ALLIANCES

ALLIANCES9 Months Ended
Sep. 30, 2020
ALLIANCES [Abstract]
Collaborative Arrangement Disclosure [Text Block]ALLIANCES BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refers to these collaborations as alliances and its partners as alliance partners. Selected financial information pertaining to alliances was as follows, including net product sales when BMS is the principal in the third-party customer sale for products subject to the alliance. Expenses summarized below do not include all amounts attributed to the activities for the products in the alliance, but only the payments between the alliance partners or the related amortization if the payments were deferred or capitalized. Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Revenues from alliances: Net product sales $ 2,116 $ 2,464 $ 7,040 $ 7,412 Alliance revenues 184 143 452 418 Total Revenues $ 2,300 $ 2,607 $ 7,492 $ 7,830 Payments to/(from) alliance partners: Cost of products sold $ 1,007 $ 1,017 $ 3,363 $ 3,116 Marketing, selling and administrative (25) (33) (103) (93) Research and development 48 11 327 32 Other (income)/expense, net (28) (15) (59) (45) Dollars in Millions September 30, December 31, Selected Alliance Balance Sheet information: Receivables – from alliance partners $ 336 $ 347 Accounts payable – to alliance partners 971 1,026 Deferred income from alliances (a) 392 431 (a) Includes unamortized upfront and milestone payments. The nature, purpose, significant rights and obligations of the parties and specific accounting policy elections for each of the Company’s significant alliances are discussed in the 2019 Form 10-K. Significant developments and updates related to alliances during the nine months ended September 30, 2020 are set forth below. Otsuka Effective January 1, 2020, Otsuka is no longer co-promoting Sprycel in the U.S. and as a result, this arrangement is no longer considered a collaboration under ASC 808. Revenues earned and fees paid to Otsuka in the Oncology Territory in 2020 are not included in the table above. bluebird BMS and bluebird jointly develop and commercialize novel disease-altering gene therapy product candidates targeting BCMA. The collaboration arrangement began in 2013 and included (i) a right for BMS to license any anti-BCMA products resulting from the collaboration, (ii) a right for bluebird to participate in the development and commercialization of any licensed products resulting from the collaboration through a 50/50 co-development and profit share in the U.S. in exchange for a reduction of milestone payments, and (iii) sales-based milestones and royalties payable to bluebird upon the commercialization of any licensed products resulting from the collaboration if bluebird declined to exercise their co-development and profit sharing rights. The options to license idecabtagene vicleucel (ide-cel, bb2121) and bb21217 were exercised in 2016 and 2017, respectively. BMS and bluebird share equally in all profits and losses relating to developing, commercializing and manufacturing ide-cel within the U.S. BMS is exclusively responsible for the development and commercialization of ide-cel outside the U.S. BMS is responsible for the worldwide development, including related funding after the substantial completion by bluebird of the ongoing Phase I clinical trial, and commercialization of bb21217. bluebird has an option to co-develop, co-promote and share equally in all profits and losses in the U.S. In the second quarter of 2020, BMS and bluebird amended their collaboration arrangement where, among other items, BMS is assuming the contract manufacturing agreements relating to ide-cel adherent lentiviral vector. Over time, BMS is assuming responsibility for manufacturing ide-cel suspension lentiviral vector outside of the U.S., with bluebird responsible for manufacturing ide-cel suspension lentiviral vector in the U.S. The parties were also released from future exclusivity related to BCMA-directed T cell therapies. In addition, BMS agreed to buy out its obligation to pay bluebird future ex-U.S. milestones and royalties on ide-cel and bb21217 for a payment of $200 million, which was included in Research and development expense in the second quarter of 2020.

ACQUISITIONS, DIVESTITURES AND

ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS (Notes)9 Months Ended
Sep. 30, 2020
Acquisitions, Divestitures and Other Arrangements [Abstract]
Mergers, Acquisitions and Dispositions Disclosures [Text Block]ACQUISITIONS, DIVESTITURES, LICENSING AND OTHER ARRANGEMENTS Acquisitions Business Combination Celgene On November 20, 2019, BMS completed the Celgene acquisition. The acquisition is expected to further position BMS as a leading biopharmaceutical company for sustained innovation and long-term growth and to address the needs of patients with cancer, inflammatory, immunologic or cardiovascular diseases through high-value innovative medicines and leading scientific capabilities. The transaction was accounted for as a business combination, which requires that assets acquired and liabilities assumed be recognized at their fair value as of the acquisition date. The purchase price allocation is preliminary and subject to change for income tax matters. The amounts recognized will be finalized as the information necessary to complete the analysis is obtained, but no later than one year after the acquisition date. The following table summarizes the provisional amounts recognized for assets acquired and liabilities assumed as of the acquisition date, as well as measurement period adjustments made year-to-date to the amounts initially recorded in 2019. The measurement period adjustments reflected in 2020 primarily resulted from completing valuations of real estate and personal property, revised future cash flow estimates for certain intangible assets, changes in the estimated tax basis of certain intangible assets based upon a tax ruling which reduced deferred income tax liabilities and other changes to certain equity investments, legal contingency and income tax liabilities. The related impact to net earnings that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial to the consolidated financial statements. Dollars in Millions Amounts Recognized as of Acquisition Date Measurement Period Adjustments Amounts Recognized as of Acquisition Date Cash and cash equivalents $ 11,179 $ — $ 11,179 Receivables 2,652 — 2,652 Inventories 4,511 — 4,511 Property, plant and equipment 1,342 (277) 1,065 Intangible assets 64,027 (100) 63,927 Otezla* assets held-for-sale 13,400 — 13,400 Other assets 3,408 45 3,453 Accounts payable (363) — (363) Income taxes payable (2,718) (47) (2,765) Deferred income tax liabilities (7,339) 2,350 (4,989) Debt (21,782) — (21,782) Other liabilities (4,017) 15 (4,002) Identifiable net assets acquired 64,300 1,986 66,286 Goodwill 15,969 (1,986) 13,983 Total consideration transferred $ 80,269 $ — $ 80,269 Asset Acquisitions MyoKardia In the fourth quarter of 2020, BMS entered into a definitive merger agreement under which BMS will acquire MyoKardia, a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious cardiovascular diseases. The acquisition will provide BMS with rights to MyoKardia’s lead asset, mavacamten, a potential first-in-class cardiovascular medicine for the treatment of obstructive hypertrophic cardiomyopathy that has completed Phase III development with an anticipated NDA submission in the first quarter of 2021. BMS, through a subsidiary, commenced a tender offer to acquire all of the issued and outstanding shares of MyoKardia’s common stock for $225.00 per share, or $13.1 billion. In November 2020, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (“HSR Act”), as amended, expired. Expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction, which remains subject to the satisfaction of the tender of a majority of the outstanding shares of MyoKardia’s common stock, a well as other customary closing conditions and regulatory approvals. BMS intends to close the acquisition of MyoKardia at the earliest possible date after the closing of the tender offer, which it currently expects to be in the fourth quarter of 2020. BMS anticipates funding the transaction through a combination of cash on hand from its operations and subject to market conditions, net proceeds received in connection with a future debt issuance. BMS expects to account for the transaction as an asset acquisition since mavacamten will represent substantially all of the fair value of the gross assets acquired. Forbius In the third quarter of 2020, BMS acquired all of the outstanding shares of Forbius, a privately held, clinical-stage protein engineering company that designs and develops biotherapeutics for the treatment of cancer and fibrotic diseases. The acquisition provides BMS with full rights to Forbius’s TGF-beta program, including the program’s lead investigational asset, AVID200, which is in Phase I development. BMS accounted for the transaction as an asset acquisition since AVID200 represented substantially all of the fair value of the gross assets acquired. The transaction price included an upfront payment of $185 million and contingent development, regulatory and sales-based milestone payments up to $815 million. The up-front payment was included in Research and development expense except for $7 million that was allocated to deferred tax assets. Other Research and development expense also includes $100 million in 2020 resulting from the occurrence of a development event attributed to the Cormorant asset acquisition completed in 2016. Divestitures The following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses). Three Months Ended September 30, Net Proceeds (a) Divestiture (Gains)/Losses Royalty and Milestone Income Dollars in Millions 2020 2019 2020 2019 2020 2019 UPSA Business $ — $ 1,510 $ — $ (1,176) $ — $ — Diabetes Business 129 163 — — (148) (171) Erbitux* 3 3 — — — — Manufacturing Operations — — — 1 — — Mature Brands and Other 41 7 1 (4) (44) (6) Total $ 173 $ 1,683 $ 1 $ (1,179) $ (192) $ (177) Nine Months Ended September 30, Net Proceeds (a) Divestiture (Gains)/Losses Royalty and Milestone Income Dollars in Millions 2020 2019 2020 2019 2020 2019 UPSA Business $ — $ 1,510 $ — $ (1,160) $ — $ — Diabetes Business 409 491 — — (404) (497) Erbitux* 10 11 — — — — Manufacturing Operations 10 3 (1) 1 — — Plavix* and Avapro*/Avalide* 7 — (12) — — — Mature Brands and Other 73 9 7 (12) (76) (8) Total $ 509 $ 2,024 $ (6) $ (1,171) $ (480) $ (505) (a) Includes royalties received subsequent to the related sale of the asset or business. UPSA Business In the third quarter of 2019, the Company sold its UPSA consumer health business, including the shares of UPSA SAS and BMS’s assets and liabilities relating to the UPSA product portfolio. The transaction was accounted for as the sale of a business. Manufacturing Operations In the second quarter of 2019, BMS agreed to sell its manufacturing and packaging facility in Anagni, Italy to Catalent. The transaction was accounted for as the sale of a business and the sale was completed in the fourth quarter of 2019. The assets were reduced to their relative fair value after considering the purchase price resulting in an impairment charge of $113 million for the nine months ended September 30, 2019 that was included in Cost of products sold. Licensing and Other Arrangements The following table summarizes the financial impact of Keytruda* royalties, up-front and milestone licensing fees for products that have not obtained commercial approval, which are included in Other (income)/expense, net. Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Keytruda * royalties $ (176) $ (132) $ (492) $ (373) Up-front licensing fees — (24) (30) (24) Contingent milestone income (16) (6) (62) (15) Amortization of deferred income (14) (14) (44) (44) Other royalties (5) (3) (16) (6) Total $ (211) $ (179) $ (644) $ (462) Dragonfly In the fourth quarter of 2020, BMS obtained a global exclusive license to Dragonfly’s interleukin-12 (IL-12) investigational immunotherapy program, including its extended half-life cytokine DF6002. BMS will be responsible for the development and any subsequent commercialization of DF6002 and its related products worldwide, including strategic decisions, regulatory responsibilities, funding, and manufacturing. Dragonfly will continue to be involved in the development of DF6002 in current and certain future Phase I/II clinical trials. The transaction included an upfront payment of $400 million and Dragonfly is eligible to receive contingent consideration comprised of development, regulatory and sales-based milestone payments up to $2.8 billion. Dragonfly will also receive royalties on global net sales.

OTHER EXPENSE (INCOME), NET

OTHER EXPENSE (INCOME), NET9 Months Ended
Sep. 30, 2020
Other Nonoperating Income (Expense) [Abstract]
Other (Income)/Expense [Text Block]OTHER (INCOME)/EXPENSE, NET Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Interest expense $ 346 $ 209 $ 1,065 $ 377 Pension and postretirement — 1,537 (6) 1,607 Royalties and licensing income (403) (356) (1,124) (967) Divestiture losses/(gains) 1 (1,179) (6) (1,171) Acquisition expenses — 7 — 475 Contingent consideration (988) — (597) — Investment income (13) (173) (99) (348) Integration expenses 195 96 535 224 Provision for restructuring 176 10 451 32 Equity investment (gains)/losses (244) 261 (724) 15 Litigation and other settlements 10 (1) 41 — Transition and other service fees (18) (7) (129) (11) Intangible asset impairment — — 21 15 Reversion excise tax — — 76 — Other 23 6 8 1 Other (income)/expense, net $ (915) $ 410 $ (488) $ 249

RESTRUCTURING

RESTRUCTURING9 Months Ended
Sep. 30, 2020
Restructuring Charges [Abstract]
Restructuring and Related Activities Disclosure [Text Block]RESTRUCTURINGA restructuring and integration plan is being implemented as an initiative to realize $2.5 billion of sustainable run-rate synergies resulting from cost savings and avoidance from the Celgene acquisition. The synergies are expected to be realized in Cost of products sold (10%), Marketing, selling and administrative expenses (55%) and Research and development expenses (35%). The majority of charges are expected to be incurred through 2022, and range between $2.5 billion to $3.0 billion. Cumulative charges of approximately $1.7 billion have been recognized including integration planning and execution expenses, employee termination benefit costs and accelerated stock-based compensation, contract termination costs and other shutdown costs associated with site exits. Cash outlays in connection with these actions are expected to be approximately $2.5 billion. Employee workforce reductions were approximately 1,400 for the nine months ended September 30, 2020. The following tables summarize the charges and activity related to the Celgene acquisition: Dollars in Millions Three Months Ended Nine Months Ended Employee termination costs $ 133 $ 386 Other termination costs 36 42 Provision for restructuring 169 428 Integration expenses 195 535 Accelerated depreciation 6 6 Asset impairments 3 42 Other — 3 Total charges $ 373 $ 1,014 Dollars in Millions Three Months Ended Nine Months Ended Marketing, selling and administrative $ 6 $ 7 Research and development 3 42 Other (income)/expense, net 364 965 Total charges $ 373 $ 1,014 Dollars in Millions Nine Months Ended Liability at January 1 $ 77 Charges 372 Change in estimates (8) Provision for restructuring (a) 364 Foreign currency translation and other 2 Payments (255) Liability at September 30 $ 188 (a) Excludes $64 million of accelerated stock-based compensation. In October 2016, a restructuring plan was announced to evolve and streamline BMS’s operating model. The majority of charges are expected to be incurred through 2020, range between $1.5 billion to $2.0 billion. Cumulative charges of approximately $1.5 billion have been recognized including employee termination benefit costs, contract termination costs, accelerated depreciation and impairment charges and other costs associated with manufacturing and R&D site exits. The remaining charges are expected to result from additional site exit costs. Cash outlays in connection with these actions are expected to be approximately 40% to 50% of the total charges. The following tables summarize the charges and activity related to the Company transformation: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Employee termination costs $ — $ 4 $ 3 $ 11 Other termination costs 7 6 20 21 Provision for restructuring 7 10 23 32 Accelerated depreciation 1 33 42 96 Asset impairments 2 9 44 119 Other shutdown costs — — 6 — Total charges $ 10 $ 52 $ 115 $ 247 Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Cost of products sold $ 3 $ 22 $ 30 $ 156 Marketing, selling and administrative — — — 1 Research and development — 20 56 58 Other (income)/expense, net 7 10 29 32 Total charges $ 10 $ 52 $ 115 $ 247 Nine Months Ended September 30, Dollars in Millions 2020 2019 Liability at December 31 $ 23 $ 99 Cease-use liability reclassification — (3) Liability at January 1 23 96 Charges 22 36 Change in estimates 1 (4) Provision for restructuring 23 32 Foreign currency translation and other — (1) Payments (40) (98) Liability at September 30 $ 6 $ 29

INCOME TAXES

INCOME TAXES9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]INCOME TAXES Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Earnings Before Income Taxes $ 2,257 $ 1,349 $ 3,580 $ 5,104 Provision/(Benefit) for Income Taxes 379 (17) 2,548 584 Effective Tax Rate 16.8 % (1.3) % 71.2 % 11.4 % An $853 million deferred tax charge resulting from an internal transfer of certain intangible assets to the U.S. and an additional $266 million GILTI tax charge upon finalization of the Otezla * divestiture tax consequences with tax authorities increased the effective tax rate by 31.3% for the nine months ended September 30, 2020. The tax impact of low jurisdictional tax rates attributed to inventory and intangible asset purchase price adjustments increased the effective tax rate and non-taxable fair value adjustments to contingent value rights decreased the effective tax rate for the nine months ended September 30, 2020. The tax impact of high jurisdictional tax rates attributed to pension settlement charges and gain on sale of the UPSA business divestiture decreased the effective tax rate in the prior periods. The tax impact of discrete items are reflected immediately and not considered in estimating the annual effective tax rate. Additional changes to the effective tax rate may occur in future periods due to various reasons including pretax earnings mix, tax reserves, cash repatriations and revised interpretations of the relevant tax code. BMS is currently under examination by a number of tax authorities, which have proposed or are considering proposing material adjustments to tax positions for issues such as transfer pricing, certain tax credits and the deductibility of certain expenses. BMS received several notices of proposed adjustments from the IRS related to transfer pricing and other tax positions for the 2008-2012 tax years. It is reasonably possible that new issues will be raised by tax authorities, which may require adjustments to the amount of unrecognized tax benefits; however, an estimate of such adjustments cannot reasonably be made at this time. Tax reserve releases due to lapse of statutes was $81 million in the three months ended September 30, 2019. It is also reasonably possible that the total amount of unrecognized tax benefits at September 30, 2020 could decrease in the range of approximately $350 million to $390 million in the next twelve months as a result of the settlement of certain tax audits and other events. The expected change in unrecognized tax benefits may result in the payment of additional taxes, adjustment of certain deferred taxes and/or recognition of tax benefits. It is reasonably possible that new issues will be raised by tax authorities that may increase unrecognized tax benefits; however, an estimate of such increases cannot reasonably be made at this time. BMS believes that it has adequately provided for all open tax years by tax jurisdiction.

EARNINGS PER SHARE

EARNINGS PER SHARE9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]EARNINGS PER SHARE Three Months Ended September 30, Nine Months Ended September 30, Amounts in Millions, Except Per Share Data 2020 2019 2020 2019 Net Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation $ 1,872 $ 1,353 $ 1,012 $ 4,495 Weighted-Average Common Shares Outstanding – Basic 2,257 1,632 2,260 1,634 Incremental Shares Attributable to Share-Based Compensation Plans 33 2 35 2 Weighted-Average Common Shares Outstanding – Diluted 2,290 1,634 2,295 1,636 Earnings per Common Share Basic $ 0.83 $ 0.83 $ 0.45 $ 2.75 Diluted 0.82 0.83 0.44 2.75 The total number of potential shares of common stock excluded from the diluted EPS computation because of the antidilutive impact was 27 million and 29 million for the three and nine months ended September 30, 2020, respectively, and was not material for the three and nine months ended September 30, 2019.

FINANCIAL INSTRUMENTS AND FAIR

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]
Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block]FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS Financial assets and liabilities measured at fair value on a recurring basis are summarized below: September 30, 2020 December 31, 2019 Dollars in Millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents - money market and other securities $ — $ 17,075 $ — $ — $ 10,448 $ — Marketable debt securities: Certificates of deposit — 1,391 — — 1,227 — Commercial paper — — — — 1,093 — Corporate debt securities — 824 — — 1,494 — Derivative assets — 74 — — 140 — Equity investments 2,927 134 — 2,020 175 — Derivative liabilities — (120) — — (40) — Contingent consideration liability: Contingent value rights 1,697 — — 2,275 — — Other acquisition related contingent consideration — — 73 — — 106 As further described in “Item 8. Financial Statements and Supplementary Data—Note 9. Financial Instruments and Fair Value Measurements” in the Company’s 2019 Form 10-K, the Company’s fair value estimates use inputs that are either (1) quoted prices for identical assets or liabilities in active markets (Level 1 inputs); (2) observable prices for similar assets or liabilities in active markets or for identical or similar assets or liabilities in markets that are not active (Level 2 inputs); or (3) unobservable inputs (Level 3 inputs). Contingent consideration obligations are recorded at their estimated fair values and these obligations are revalued each reporting period until the related contingencies are resolved. The contingent value rights are adjusted to fair value using the traded price of the securities at the end of each reporting period. The fair value measurements for other contingent consideration liabilities are estimated using probability-weighted discounted cash flow approaches that are based on significant unobservable inputs related to product candidates acquired in business combinations and are reviewed quarterly. These inputs include, as applicable, estimated probabilities and timing of achieving specified development and regulatory milestones, estimated annual sales and the discount rate used to calculate the present value of estimated future payments. Significant changes which increase or decrease the probabilities of achieving the related development and regulatory events, shorten or lengthen the time required to achieve such events, or increase or decrease estimated annual sales would result in corresponding increases or decreases in the fair values of these obligations. The fair value of our contingent consideration as of September 30, 2020 was calculated using the following significant unobservable inputs: Ranges (weighted average) utilized as of: Inputs September 30, 2020 Discount rate 2.2% to 2.7% (2.4%) Probability of payment 0% to 80% (2.7%) Projected year of payment for development and regulatory milestones 2021 to 2025 There were no transfers between levels 1, 2 and 3 during the nine months ended September 30, 2020. The following table represents a roll-forward of the fair value of level 3 instruments: Dollars in Millions Nine Months Ended September 30, 2020 Fair value as of January 1 $ 106 Changes in estimated fair value (35) Foreign exchange 2 Fair value as of September 30 $ 73 Available-for-sale Debt Securities and Equity Investments Changes in fair value of equity investments are included in Other (income)/expense, net. The following table summarizes available-for-sale debt securities and equity investments: September 30, 2020 December 31, 2019 Dollars in Millions Amortized Cost Gross Unrealized Amortized Cost Gross Unrealized Gains Losses Fair Value Gains Losses Fair Value Certificates of deposit $ 1,391 $ — $ — $ 1,391 $ 1,227 $ — $ — $ 1,227 Commercial paper — — — — 1,093 — — 1,093 Corporate debt securities 807 17 — 824 1,487 8 (1) 1,494 Total available-for-sale debt securities (a) $ 2,198 $ 17 $ — $ 2,215 $ 3,807 $ 8 $ (1) $ 3,814 Equity investments 3,061 2,195 Total $ 5,276 $ 6,009 (a) All marketable debt securities mature within five years as of September 30, 2020 and December 31, 2019. Equity investments not measured at fair value and excluded from the above fair value table were limited partnerships and other equity method investments of $496 million at September 30, 2020 and $429 million at December 31, 2019 and other equity investments without readily determinable fair values of $735 million at September 30, 2020 and $781 million at December 31, 2019. These amounts are included in Other non-current assets. Upward adjustments to equity investments without readily determinable fair values for the three and nine months ended September 30, 2020 were $46 million and $318 million, respectively, resulting from observable price changes for similar securities for the same issuer and were recorded in Other (income)/expense, net. Downward adjustments to equity investments without readily determinable fair values for the three and nine months ended September 30, 2020 were $2 million and $203 million, respectively. The following table summarizes the net gain/(loss) recorded for equity investments with readily determinable fair values held as of September 30, 2020 and 2019: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Net gain/(loss) recognized $ 170 $ (235) $ 577 $ (81) Less: Net gain recognized for equity investments sold — — — 14 Net unrealized gain/(loss) on equity investments held $ 170 $ (235) $ 577 $ (95) Qualifying Hedges and Non-Qualifying Derivatives Cash Flow Hedges — Foreign currency forward contracts are used to hedge certain forecasted intercompany inventory purchases and sales transactions and certain foreign currency transactions. The fair value for contracts designated as cash flow hedges are temporarily reported in Accumulated other comprehensive loss and included in earnings when the hedged item affects earnings. The majority of the net gain or loss on foreign currency forward contracts is expected to be reclassified to net earnings (primarily included in Cost of products sold and Other (income)/expense, net) within the next 12 months. The notional amount of outstanding foreign currency forward contracts was primarily attributed to the euro of $3.0 billion and Japanese yen of $1.4 billion at September 30, 2020. The earnings impact related to discontinued cash flow hedges and hedge ineffectiveness was not material during all periods presented. Cash flow hedge accounting is discontinued when the forecasted transaction is no longer probable of occurring within 60 days after the originally forecasted date or when the hedge is no longer effective. Assessments to determine whether derivatives designated as qualifying hedges are highly effective in offsetting changes in the cash flows of hedged items are performed at inception and on a quarterly basis. Foreign currency forward contracts not designated as hedging instruments are used to offset exposures in certain foreign currency denominated assets, liabilities and earnings. Changes in the fair value of these derivatives are recognized in earnings as they occur. BMS may hedge a portion of its future foreign currency exposure by utilizing a strategy that involves both a purchased local currency put option and a written local currency call option that are accounted for as hedges of future sales denominated in that local currency. Specifically, BMS sells (or writes) a local currency call option and purchases a local currency put option with the same expiration dates and local currency notional amounts but with different strike prices. The premium collected from the sale of the call option is equal to the premium paid for the purchased put option, resulting in no net premium being paid. This combination of transactions is generally referred to as a “zero-cost collar.” The expiration dates and notional amounts correspond to the amount and timing of forecasted foreign currency sales. If the U.S. Dollar weakens relative to the currency of the hedged anticipated sales, the purchased put option value reduces to zero and BMS benefits from the increase in the U.S. Dollar equivalent value of our anticipated foreign currency cash flows; however, this benefit would be capped at the strike level of the written call, which forms the upper end of the collar. Net Investment Hedges — Non-U.S. Dollar borrowings of €950 million ($1.1 billion) at September 30, 2020 are designated as net investment hedges to hedge euro currency exposures of the net investment in certain foreign affiliates and are recognized in long-term debt. The effective portion of foreign exchange gain on the remeasurement of euro debt was included in the foreign currency translation component of Accumulated other comprehensive loss with the related offset in long-term debt. Contract fair value changes are recorded in the foreign currency translation component of Other Comprehensive (Loss)/Income with a related offset in Other non-current assets or Other non-current liabilities. Cross-currency interest rate swap contracts of $400 million at September 30, 2020 are designated to hedge Japanese yen currency exposure of BMS’s net investment in its Japan subsidiaries. Contract fair value changes are recorded in the foreign currency translation component of Other Comprehensive (Loss)/Income with a related offset in Other non-current assets or Other non-current liabilities. Fair Value Hedges — Fixed to floating interest rate swap contracts are designated as fair value hedges and used as an interest rate risk management strategy to create an appropriate balance of fixed and floating rate debt. The contracts and underlying debt for the hedged benchmark risk are recorded at fair value. The effective interest rate for the contracts is one-month LIBOR (0.15% as of September 30, 2020) plus an interest rate spread of 4.6%. Gains or losses resulting from changes in fair value of the underlying debt attributable to the hedged benchmark interest rate risk are recorded in interest expense with an associated offset to the carrying value of debt. Since the specific terms and notional amount of the swap are intended to align with the debt being hedged, all changes in fair value of the swap are recorded in interest expense with an associated offset to the derivative asset or liability on the consolidated balance sheet. As a result, there was no net impact in earnings. When the underlying swap is terminated prior to maturity, the fair value adjustment to the underlying debt is amortized as a reduction to interest expense over the remaining term of the debt. In the second quarter of 2019, deal contingent forward starting interest rate swap contracts were entered into, with an aggregate notional principal amount of $10.4 billion to hedge interest rate risk associated with the anticipated issuance of long-term debt to fund the Celgene acquisition and the forward starting interest rate swap option contracts were terminated. The deal contingent forward starting interest rate swap contracts were terminated upon the completion of the Celgene acquisition. The following table summarizes the fair value of outstanding derivatives: September 30, 2020 December 31, 2019 Asset (a) Liability (b) Asset (a) Liability (b) Dollars in Millions Notional Fair Value Notional Fair Value Notional Fair Value Notional Fair Value Derivatives designated as hedging instruments: Interest rate swap contracts $ 255 $ 27 $ — $ — $ 255 $ 6 $ — $ — Cross-currency interest rate swap contracts 225 2 175 (1) 175 2 125 (1) Foreign currency forward contracts 1,904 18 3,422 (116) 766 27 980 (20) Derivatives not designated as hedging instruments: Foreign currency forward contracts 1,108 27 478 (3) 2,342 91 1,173 (10) Foreign currency zero-cost collar contracts 123 — 65 — 2,482 14 2,235 (9) (a) Included in Other current assets and Other non-current assets. (b) Included in Other current liabilities and Other non-current liabilities. The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments: Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Dollars in Millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Interest rate swap contracts $ — $ (7) $ — $ (21) Cross-currency interest rate swap contracts — (3) — (8) Foreign currency forward contracts (5) 14 (63) (41) Foreign currency zero-cost collar contracts — — — 1 Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Dollars in Millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Interest rate swap contracts $ — $ (6) $ — $ (18) Cross-currency interest rate swap contracts — (2) — (6) Foreign currency forward contracts (20) (9) (76) (11) Forward starting interest rate swap options — — — 35 Deal contingent forward starting interest rate swap — — — 240 The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive (Loss)/Income: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Derivatives qualifying as cash flow hedges Foreign currency forward contracts gain/(loss): Recognized in Other Comprehensive (Loss)/Income (a) $ (128) $ 63 $ (65) $ 102 Reclassified to Cost of products sold (17) (20) (69) (76) Derivatives qualifying as net investment hedges Cross-currency interest rate swap contracts gain/(loss): Recognized in Other Comprehensive (Loss)/Income (11) 2 (1) 4 Non-derivatives qualifying as net investment hedges Non-U.S. dollar borrowings gain/(loss): Recognized in Other Comprehensive (Loss)/Income (39) 41 (51) 43 (a) The amount is expected to be reclassified into earnings in the next 12 months. Debt Obligations Short-term debt obligations include: Dollars in Millions September 30, December 31, Non-U.S. short-term borrowings $ 183 $ 351 Current portion of long-term debt 3,250 2,763 Other 152 232 Total $ 3,585 $ 3,346 Long-term debt and the current portion of long-term debt include: Dollars in Millions September 30, December 31, Principal Value $ 42,896 $ 44,335 Adjustments to Principal Value: Fair value of interest rate swap contracts 27 6 Unamortized basis adjustment from swap terminations 155 175 Unamortized bond discounts and issuance costs (256) (280) Unamortized purchase price adjustments of Celgene debt 1,792 1,914 Total $ 44,614 $ 46,150 Current portion of long-term debt $ 3,250 $ 2,763 Long-term debt 41,364 43,387 Total $ 44,614 $ 46,150 The fair value of long-term debt was $52.7 billion at September 30, 2020 and $50.7 billion at December 31, 2019 valued using Level 2 inputs, which are based upon the quoted market prices for the same or similar debt instruments. The fair value of short-term borrowings approximates the carrying value due to the short maturities of the debt instruments. Interest payments were $1.3 billion and $166 million for the nine months ended September 30, 2020 and 2019, respectively, net of amounts related to interest rate swap contracts. In the second quarter of 2019, BMS issued an aggregate principal amount of $19.0 billion of floating rate and fixed rate unsecured senior notes. The notes rank equally in right of payment with all of the Company’s existing and future senior unsecured indebtedness and the fixed rate notes are redeemable at any time, in whole, or in part, at varying specified redemption prices plus accrued and unpaid interest. During the third quarter of 2020, the $1.5 billion 2.875% Notes matured and were repaid. During the first quarter of 2019, the $750 million 1.600% Notes and the $500 million 1.750% Notes matured and were repaid. As of September 30, 2020, BMS had four separate revolving credit facilities totaling $6.0 billion, which consisted of a 364-day $2.0 billion facility expiring in January 2021, a $1.0 billion facility expiring in January 2022 and two five-year $1.5 billion facilities that were extended to September 2023 and July 2024, respectively. The facilities provide for customary terms and conditions with no financial covenants and may be used to provide backup liquidity for BMS’s commercial paper borrowings. BMS’s $1.0 billion facility and its two $1.5 billion revolving facilities are extendable annually by one year on the anniversary date with the consent of the lenders. No borrowings were outstanding under revolving credit facilities at September 30, 2020 or December 31, 2019.

RECEIVABLES

RECEIVABLES9 Months Ended
Sep. 30, 2020
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Receivables [Text Block]RECEIVABLES Dollars in Millions September 30, December 31, Trade receivables $ 7,168 $ 6,888 Less charge-backs and cash discounts (371) (391) Less allowance for expected credit loss (20) (21) Net trade receivables 6,777 6,476 Alliance, royalties, VAT and other 1,285 1,209 Receivables $ 8,062 $ 7,685 Non-U.S. receivables sold on a nonrecourse basis were $788 million and $580 million for the nine months ended September 30, 2020 and 2019, respectively. Receivables from the three largest customers in the U.S. represented approximately 56% and 50% of total trade receivables at September 30, 2020 and December 31, 2019, respectively.

INVENTORIES

INVENTORIES9 Months Ended
Sep. 30, 2020
Inventory, Net [Abstract]
Inventories [Text Block]INVENTORIES Dollars in Millions September 30, December 31, Finished goods $ 822 $ 2,227 Work in process 2,069 3,267 Raw and packaging materials 221 172 Total inventories $ 3,112 $ 5,666 Inventories $ 1,949 $ 4,293 Other non-current assets 1,163 1,373 Total inventories include fair value adjustments resulting from the Celgene acquisition of $883 million at September 30, 2020 and $3.5 billion at December 31, 2019. Other non-current assets include inventory expected to remain on hand beyond one year in both periods.

PROPERTY, PLANT AND EQUIPMENT

PROPERTY, PLANT AND EQUIPMENT9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Text Block]PROPERTY, PLANT AND EQUIPMENT Dollars in Millions September 30, December 31, Land $ 188 $ 187 Buildings 5,708 6,336 Machinery, equipment and fixtures 3,101 3,157 Construction in progress 409 527 Gross property, plant and equipment 9,406 10,207 Less accumulated depreciation (3,666) (3,955) Property, plant and equipment (a) $ 5,740 $ 6,252 (a) Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information. Depreciation expense was $136 million and $451 million for the three and nine months ended September 30, 2020 and $135 million and $401 million for the three and nine months ended September 30, 2019, respectively.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]GOODWILL AND OTHER INTANGIBLE ASSETS Dollars in Millions Estimated Useful Lives September 30, December 31, Goodwill (a) $ 20,517 $ 22,488 Other intangible assets: Licenses 5 – 15 years 461 482 Acquired developed product rights (a) 3 – 15 years 59,651 46,827 Capitalized software 3 – 10 years 1,357 1,297 IPRD 6,600 19,500 Gross other intangible assets 68,069 68,106 Less accumulated amortization (11,371) (4,137) Other intangible assets $ 56,698 $ 63,969 (a) Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information. In the nine months ended September 30, 2020, $12.9 billion of IPRD was reclassified to acquired developed product rights upon approval in the U.S. for Reblozyl for the treatment of anemia in adults with lower-risk MDS, Zeposia and Onureg . Amortization expense of other intangible assets was $2.5 billion and $7.3 billion for the three and nine months ended September 30, 2020 and $52 million and $156 million for the three and nine months ended September 30, 2019, respectively.

SUPPLEMENTAL FINANCIAL INFORMAT

SUPPLEMENTAL FINANCIAL INFORMATION9 Months Ended
Sep. 30, 2020
Supplemental Financial Information [Abstract]
Additional Financial Information Disclosure [Text Block]SUPPLEMENTAL FINANCIAL INFORMATION Dollars in Millions September 30, December 31, 2019 Prepaid and refundable income taxes $ 1,633 $ 754 Research and development 462 410 Equity investments 126 — Other (a) 890 819 Other current assets $ 3,111 $ 1,983 (a) Includes restricted cash of $84 million at September 30, 2020. Dollars in Millions September 30, December 31, 2019 Equity investments $ 4,166 $ 3,405 Inventories 1,163 1,373 Operating leases 718 704 Pension and postretirement 222 456 Restricted cash (a) 341 390 Other 286 276 Other non-current assets $ 6,896 $ 6,604 (a) Restricted cash consists of escrow for litigation settlements and funds restricted for annual Company contributions to the defined contribution plan in the U.S. Restricted cash of $425 million was included in cash, cash equivalents and restricted cash at September 30, 2020 in the consolidated statements of cash flows. Dollars in Millions September 30, December 31, 2019 Rebates and returns $ 5,747 $ 4,275 Income taxes payable 686 1,517 Employee compensation and benefits 1,069 1,457 Research and development 1,315 1,324 Dividends 1,043 1,025 Interest 380 493 Royalties 398 418 Operating leases 136 133 Contingent value rights 1,680 — Other 1,984 1,871 Other current liabilities $ 14,438 $ 12,513 Dollars in Millions September 30, December 31, 2019 Income taxes payable $ 5,025 $ 5,368 Contingent value rights 17 2,275 Pension and postretirement 871 725 Operating leases 722 672 Deferred income 361 424 Deferred compensation 301 287 Other 268 350 Other non-current liabilities $ 7,565 $ 10,101

EQUITY

EQUITY9 Months Ended
Sep. 30, 2020
Equity [Abstract]
Stockholders' Equity Note Disclosure [Text Block]EQUITY The following table summarizes changes in equity for the nine months ended September 30, 2020: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and Shares in Millions Shares Par Value Shares Cost Balance at December 31, 2019 2,923 $ 292 $ 43,709 $ (1,520) $ 34,474 672 $ (25,357) $ 100 Net loss — — — — (775) — — 9 Other Comprehensive Loss — — — (29) — — — — Cash dividends declared (a) — — — — (1,028) — — — Share repurchase program — — — — — 1 (81) — Stock compensation — — (455) — — (13) 681 — Distributions — — — — — — — (43) Balance at March 31, 2020 2,923 292 43,254 (1,549) 32,671 660 (24,757) 66 Net loss — — — — (85) — — 5 Other Comprehensive Loss — — — (7) — — — — Cash dividends declared (a) — — — — (1,021) — — — Stock repurchase program — — 1,400 — — 16 (1,400) — Stock compensation — — (210) — — (7) 506 — Distributions — — — — — — — (5) Balance at June 30, 2020 2,923 292 44,444 (1,556) 31,565 669 (25,651) 66 Net earnings — — — — 1,872 — — 6 Other Comprehensive Loss — — — (143) — — — — Cash dividends declared (a) — — — — (1,023) — — — Stock repurchase program — — — — — — — — Stock compensation — — (9) — — (6) 367 — Distributions — — — — — — — — Balance at September 30, 2020 2,923 $ 292 $ 44,435 $ (1,699) $ 32,414 663 $ (25,284) $ 72 (a) Cash dividends declared per common share were $0.45 for the three months ended March 31, 2020, June 30, 2020 and September 30, 2020. The following table summarizes changes in equity for the nine months ended September 30, 2019: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and Shares in Millions Shares Par Value Shares Cost Balance at December 31, 2018 2,208 $ 221 $ 2,081 $ (2,762) $ 34,065 576 $ (19,574) $ 96 Accounting change - cumulative effect (a) — — — — 5 — — — Adjusted balance at January 1, 2019 2,208 221 2,081 (2,762) 34,070 576 (19,574) 96 Net earnings — — — — 1,710 — — 5 Other Comprehensive Income — — — 118 — — — — Cash dividends declared (b) — — — — (671) — — — Stock compensation — — 22 — — (4) 3 — Distributions — — — — — — — (2) Balance at March 31, 2019 2,208 221 2,103 (2,644) 35,109 572 (19,571) 99 Net earnings — — — — 1,432 — — 7 Other Comprehensive Income — — — 23 — — — — Cash dividends declared (b) — — — — (671) — — — Stock compensation — — 47 — — — — — Distributions — — — — — — — (4) Balance at June 30, 2019 2,208 221 2,150 (2,621) 35,870 572 (19,571) 102 Net earnings — — — — 1,353 — — 13 Other Comprehensive Income — — — 1,158 — — — — Cash dividends declared (b) — — — — (668) — — — Stock repurchase program — — — — — 7 (300) — Stock compensation — — 56 — — — — — Distributions — — — — — — — (9) Balance at September 30, 2019 2,208 $ 221 $ 2,206 $ (1,463) $ 36,555 579 $ (19,871) $ 106 (a) Refer to “—Note 1. Accounting Policies and Recently Issued Accounting Standards” in the Company’s 2019 Form 10-K for additional information. (b) Cash dividends declared per common share were $0.41 for the three months ended March 31, 2019, June 30, 2019 and September 30, 2019. BMS has a share repurchase program, authorized by its Board of Directors, allowing for repurchases of its shares. Treasury stock is recognized at the cost to reacquire the shares. Shares issued from treasury are recognized utilizing the first-in first-out method. The outstanding share repurchase authority authorization under the program was $1.0 billion as of December 31, 2019. In February 2020, the Board of Directors approved an increase of $5.0 billion to the share repurchase authorization for BMS common stock. BMS repurchased 1.4 million shares of its common stock for $81 million during the nine months ended September 30, 2020. The remaining share repurchase capacity under the share repurchase program was approximately $5.9 billion as of September 30, 2020. In the fourth quarter of 2019, BMS executed accelerated share repurchase (“ASR”) agreements to repurchase an aggregate $7 billion of common stock. The ASR was funded with cash on-hand. In the fourth quarter of 2019, approximately 99 million shares of common stock (80% of the $7 billion aggregate repurchase price) were received by BMS and included in treasury stock. In the second quarter of 2020, the agreement was settled and approximately 16 million shares of common stock were received by BMS and transferred to treasury stock. The Company repurchased 6.5 million shares of its common stock for $300 million in the third quarter of 2019. The components of Other Comprehensive (Loss)/Income were as follows: 2020 2019 Dollars in Millions Pretax Tax After Tax Pretax Tax After Tax Three Months Ended September 30, Derivatives qualifying as cash flow hedges: Unrealized gain/(losses) $ (128) $ 10 $ (118) $ 63 $ (8) $ 55 Reclassified to net earnings (a) (17) 3 (14) (20) 3 (17) Derivatives qualifying as cash flow hedges (145) 13 (132) 43 (5) 38 Pension and postretirement benefits: Actuarial losses (16) 3 (13) (126) 27 (99) Amortization (b) 9 (2) 7 12 (2) 10 Settlements (b) 3 (1) 2 1,550 (345) 1,205 Pension and postretirement benefits (4) — (4) 1,436 (320) 1,116 Available-for-sale debt securities: Unrealized gains/(losses) (4) 2 (2) 6 (2) 4 Foreign currency translation (16) 11 (5) 10 (10) — Other Comprehensive (Loss)/Income $ (169) $ 26 $ (143) $ 1,495 $ (337) $ 1,158 Nine Months Ended September 30, Derivatives qualifying as cash flow hedges: Unrealized gains/(losses) $ (65) $ 4 $ (61) $ 102 $ (12) $ 90 Reclassified to net earnings (a) (69) 9 (60) (76) 10 (66) Derivatives qualifying as cash flow hedges (134) 13 (121) 26 (2) 24 Pension and postretirement benefits: Actuarial losses (28) 6 (22) (140) 30 (110) Amortization (b) 27 (5) 22 45 (8) 37 Settlements (b) 7 (2) 5 1,643 (366) 1,277 Pension and postretirement benefits 6 (1) 5 1,548 (344) 1,204 Available-for-sale securities: Unrealized gains 10 (2) 8 42 (2) 40 Realized gains/(losses) (1) — (1) 3 — 3 Available-for-sale securities 9 (2) 7 45 (2) 43 Foreign currency translation (81) 11 (70) 39 (11) 28 Total Other Comprehensive (Loss)/Income $ (200) $ 21 $ (179) $ 1,658 $ (359) $ 1,299 (a) Included in Cost of products sold. (b) Included in Other (income)/expense, net. The accumulated balances related to each component of Other Comprehensive (Loss)/Income, net of taxes, were as follows: Dollars in Millions September 30, December 31, Derivatives qualifying as cash flow hedges $ (102) $ 19 Pension and postretirement benefits (894) (899) Available-for-sale debt securities 13 6 Foreign currency translation (716) (646) Accumulated other comprehensive loss $ (1,699) $ (1,520)

PENSION AND POSTRETIREMENT BENE

PENSION AND POSTRETIREMENT BENEFIT PLANS9 Months Ended
Sep. 30, 2020
Retirement Benefits [Abstract]
Pension and Other Postretirement Benefits [Text Block]RETIREMENT BENEFITS The net periodic benefit cost of defined benefit pension plans includes: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Service cost – benefits earned during the year $ 12 $ 6 $ 36 $ 18 Interest cost on projected benefit obligation 11 20 30 101 Expected return on plan assets (26) (39) (73) (173) Amortization of prior service credits (1) (1) (3) (3) Amortization of net actuarial loss 12 14 33 49 Curtailments and settlements 3 1,550 7 1,643 Net periodic pension benefit cost $ 11 $ 1,550 $ 30 $ 1,635 Pension settlement charges were recognized after determining the annual lump sum payments will exceed the annual interest and service costs for certain pension plans. The charges included the acceleration of a portion of unrecognized actuarial losses. Non-current pension liabilities were $588 million at September 30, 2020 and $569 million at December 31, 2019. Defined contribution plan expense in the U.S. was approximately $70 million and $220 million for the three and nine months ended September 30, 2020 and approximately $50 million and $140 million for the three and nine months ended September 30, 2019, respectively. Comprehensive medical and group life benefits are provided for substantially all U.S. retirees electing to participate in comprehensive medical and group life plans and to a lesser extent certain benefits for non-U.S. employees. The net periodic benefit credits were not material in both periods. As a result of the Bristol-Myers Squibb Retirement Income Plan termination in 2019, $381 million of assets held in a separate account within the Pension Trust used to fund retiree medical plan payments was reverted back to the Company, resulting in an excise tax of $76 million in the first quarter of 2020. In December 2018, BMS announced plans to fully terminate the Plan. Pension obligations related to the Plan were to be distributed through a combination of lump sum payments to eligible Plan participants who elected such payments and through the purchase of group annuity contracts from wholly owned insurance subsidiaries of Athene Holding Ltd. (“Athene”). In the third quarter of 2019, $1.3 billion was distributed to participants who elected lump sum payments during the election window and a group annuity contract was purchased from Athene, which irrevocably assumed the obligation, for $2.4 billion for most of the remaining plan participants. These transactions resulted in a $1.5 billion non-cash pre-tax pension settlement charge in the third quarter of 2019. The remaining plan obligation of approximately $200 million was settled through the purchase of an additional group annuity contract from Athene in the fourth quarter of 2019.

EMPLOYEE STOCK BENEFIT PLANS Em

EMPLOYEE STOCK BENEFIT PLANS Employee Stock Benefit Plans (Notes)9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement, Disclosure [Abstract]
Share-based Payment Arrangement [Text Block]EMPLOYEE STOCK BENEFIT PLANS Stock-based compensation expense was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Cost of products sold $ 9 $ 4 $ 28 $ 11 Marketing, selling and administrative 81 32 255 90 Research and development 78 20 261 56 Other (income)/expense, net 17 — 64 — Total stock-based compensation expense $ 185 $ 56 $ 608 $ 157 Income tax benefit (a) $ 38 $ 10 $ 124 $ 29 (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $1 million and $29 million for the three and nine months ended September 30, 2020 and was not material for the three and nine months ended September 30, 2019. The total stock-based compensation expense for the three and nine months ended September 30, 2020 includes $85 million and $306 million, respectively, related to the Celgene post-combination service period for the replacement awards and $17 million and $64 million, respectively, of accelerated vesting of the replacement awards related to the Celgene acquisition. It also includes $5 million related to CVR obligation on unvested stock awards for the nine months ended September 30, 2020. The number of units granted and the weighted-average fair value on the grant date for the nine months ended September 30, 2020 were as follows: Units in Millions Units Weighted-Average Fair Value Restricted stock units 13.0 $ 53.62 Market share units 0.9 53.92 Performance share units 1.4 55.61 Dollars in Millions Stock Options Restricted Stock Units Market Share Units Performance Share Units Unrecognized compensation cost $ 54 $ 991 $ 53 $ 93 Expected weighted-average period in years of compensation cost to be recognized 1.5 2.6 3.0 1.8

LEGAL PROCEEDINGS AND CONTINGEN

LEGAL PROCEEDINGS AND CONTINGENCIES9 Months Ended
Sep. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Legal Proceedings and Contingencies [Text Block]LEGAL PROCEEDINGS AND CONTINGENCIES BMS and certain of its subsidiaries are involved in various lawsuits, claims, government investigations and other legal proceedings that arise in the ordinary course of business. These claims or proceedings can involve various types of parties, including governments, competitors, customers, suppliers, service providers, licensees, employees, or shareholders, among others. These matters may involve patent infringement, antitrust, securities, pricing, sales and marketing practices, environmental, commercial, contractual rights, licensing obligations, health and safety matters, consumer fraud, employment matters, product liability and insurance coverage, among others. The resolution of these matters often develops over a long period of time and expectations can change as a result of new findings, rulings, appeals or settlement arrangements. Legal proceedings that are significant or that BMS believes could become significant or material are described below. While BMS does not believe that any of these matters, except as otherwise specifically noted below, will have a material adverse effect on its financial position or liquidity as BMS believes it has substantial defenses in the matters, the outcomes of BMS’s legal proceedings and other contingencies are inherently unpredictable and subject to significant uncertainties. There can be no assurance that there will not be an increase in the scope of one or more of these pending matters or any other or future lawsuits, claims, government investigations or other legal proceedings will not be material to BMS’s financial position, results of operations or cash flows for a particular period. Furthermore, failure to enforce BMS’s patent rights would likely result in substantial decreases in the respective product revenues from generic competition. Unless otherwise noted, BMS is unable to assess the outcome of the respective matters nor is it able to estimate the possible loss or range of losses that could potentially result for such matters. Contingency accruals are recognized when it is probable that a liability will be incurred and the amount of the related loss can be reasonably estimated. Developments in legal proceedings and other matters that could cause changes in the amounts previously accrued are evaluated each reporting period. For a discussion of BMS’s tax contingencies, see “—Note 7. Income Taxes”. INTELLECTUAL PROPERTY Anti-PD-1 Antibody Litigation In September 2015, Dana-Farber Cancer Institute (“Dana-Farber”) filed a complaint in the U.S. District Court for the District of Massachusetts seeking to correct the inventorship on up to six related U.S. patents directed to methods of treating cancer using PD-1 and PD-L1 antibodies. Specifically, Dana-Farber is seeking to add two scientists as inventors to these patents. In October 2017, Pfizer was allowed to intervene in this case alleging that one of the scientists identified by Dana-Farber was employed by a company eventually acquired by Pfizer during the relevant period. In February 2019, BMS settled the lawsuit with Pfizer. A bench trial in the lawsuit with Dana-Farber took place in February 2019. In May 2019, the Court issued an opinion ruling that the two scientists should be added as inventors to the patents. The decision was appealed to the U.S. Court of Appeals for the Federal Circuit and the Federal Circuit affirmed the District Court opinion. BMS filed a petition to reconsider the decision with the Federal Circuit en banc , which was denied in October 2020. In June 2019, Dana-Farber filed a new lawsuit in the District of Massachusetts against BMS seeking damages as a result of the Court’s decision adding the scientists as inventors. CAR T On October 18, 2017, the day on which the FDA approved Kite Pharma, Inc.’s (“Kite”) Yescarta* product, Juno, along with Sloan Kettering Institute for Cancer Research (“SKI”), filed a complaint against Kite in the U.S. District Court for the Central District of California. The complaint alleged that Yescarta* infringes certain claims of U.S. Patent No. 7,446,190 (“the ’190 Patent”) concerning CAR T cell technologies. Kite filed an answer and counterclaims asserting non-infringement and invalidity of the ’190 Patent. In December 2019, following an eight-day trial, the jury rejected Kite’s defenses, finding that Kite willfully infringed the ’190 Patent and awarding to Juno and SKI a reasonable royalty consisting of a $585 million upfront payment and a 27.6% running royalty on Kite’s sales of Yescarta* through the expiration of the ’190 Patent in August 2024. In January 2020, Kite renewed its previous motion for judgment as a matter of law and also moved for a new trial, and Juno filed a motion seeking enhanced damages, supplemental damages, ongoing royalties, and prejudgment interest. In March 2020, the Court denied both of Kite’s motions in their entirety. In April 2020, the Court granted in part Juno’s motion and entered a final judgment awarding to Juno and SKI approximately $1.2 billion in royalties, interest and enhanced damages and a 27.6% running royalty on Kite’s sales of Yescarta * from December 13, 2019 through the expiration of the ’190 Patent in August 2024. In April 2020, Kite appealed the final judgment to the U.S. Court of Appeals for the Federal Circuit. No date has been scheduled for an oral hearing on the appeal. Eliquis - U.S. In 2017, BMS received Notice Letters from twenty-five generic companies notifying BMS that they had filed aNDAs containing paragraph IV certifications seeking approval of generic versions of Eliquis . As a result, two Eliquis patents listed in the FDA Orange Book are being challenged: the composition of matter patent claiming apixaban specifically and a formulation patent. In response, BMS, along with its partner Pfizer, initiated patent infringement actions under the Hatch-Waxman Act against all generic filers in the U.S. District Court for the District of Delaware in April 2017. In August 2017, the U.S. Patent and Trademark Office granted patent term restoration to the composition of matter patent to November 2026, thereby restoring the term of the Eliquis composition of matter patent, which is BMS’s basis for projected LOE. BMS settled with a number of aNDA filers. These settlements do not affect BMS’s projected LOE for Eliquis . A trial with the remaining aNDA filers took place in late 2019. On August 5, 2020, the U.S. District Court issued a decision finding that the remaining aNDA filers’ products infringed the Eliquis composition of matter and formulation patents and that both Eliquis patents are not invalid. The remaining aNDA filers have appealed to the Court of Appeals for the Federal Circuit. Plavix* - Australia Sanofi was notified that, in August 2007, GenRx Proprietary Limited (“GenRx”) obtained regulatory approval of an application for clopidogrel bisulfate 75mg tablets in Australia. GenRx, formerly a subsidiary of Apotex Inc., subsequently changed its name to Apotex (“GenRx-Apotex”). In August 2007, GenRx-Apotex filed an application in the Federal Court of Australia seeking revocation of Sanofi’s Australian Patent No. 597784 (Case No. NSD 1639 of 2007). Sanofi filed counterclaims of infringement and sought an injunction. On September 21, 2007, the Federal Court of Australia granted Sanofi’s injunction. A subsidiary of BMS was subsequently added as a party to the proceedings. In February 2008, a second company, Spirit Pharmaceuticals Pty. Ltd., also filed a revocation suit against the same patent. This case was consolidated with the GenRx-Apotex case. On August 12, 2008, the Federal Court of Australia held that claims of Patent No. 597784 covering clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate salts were valid. The Federal Court also held that the process claims, pharmaceutical composition claims, and claim directed to clopidogrel and its pharmaceutically acceptable salts were invalid. BMS and Sanofi filed notices of appeal in the Full Court of the Federal Court of Australia (“Full Court”) appealing the holding of invalidity of the claim covering clopidogrel and its pharmaceutically acceptable salts, process claims, and pharmaceutical composition claims. GenRx-Apotex appealed the holding of validity of the clopidogrel bisulfate, hydrochloride, hydrobromide, and taurocholate claims. On September 29, 2009, the Full Court held all of the claims of Patent No. 597784 invalid. In March 2010, the High Court of Australia denied a request by BMS and Sanofi to hear an appeal of the Full Court decision. The case was remanded to the Federal Court for further proceedings related to damages sought by GenRx-Apotex. BMS and GenRx-Apotex settled, and the GenRx-Apotex case was dismissed. The Australian government intervened in this matter seeking maximum damages up to 449 million AUD ($316 million), plus interest, which would be split between BMS and Sanofi, for alleged losses experienced for paying a higher price for branded Plavix* during the period when the injunction was in place. BMS and Sanofi dispute that the Australian government is entitled to any damages. A trial was concluded in September 2017. In April 2020, the Federal Court issued a decision dismissing the Australian government's claim for damages. In May 2020, the Australian government appealed the Federal Court’s decision. Pomalyst - Canada Celgene received a Notice of Allegation in January 2020 from Natco Pharma (Canada) Inc. (“Natco Canada”) notifying Celgene that it had filed an Abbreviated New Drug Submission (“aNDS”) with Canada’s Minister of Health with respect to certain of Celgene’s Canadian patents. Natco Canada is seeking to market a generic version of Pomalyst in Canada. In response, Celgene initiated a patent infringement action in the Federal Court of Canada. Natco Canada alleges that the asserted patents are invalid and/or not infringed. A trial is scheduled to begin on November 15, 2021. Celgene received two Notices of Allegation in March 2020 from Dr. Reddy’s Laboratories Ltd. (“DRL Canada”) notifying Celgene that it had filed an aNDS with Canada’s Minister of Health with respect to certain of Celgene’s Canadian patents. DRL Canada is seeking to market a generic version of Pomalyst in Canada. In response, Celgene initiated two patent infringement actions in the Federal Court of Canada. DRL Canada alleges that the asserted patents are invalid and/or not infringed. A trial is scheduled to begin on January 17, 2022. Pomalyst - U.S. Beginning in 2017, Celgene received Notice letters on behalf of Teva Pharmaceuticals USA, Inc. (“Teva”); Apotex Inc. (“Apotex”) and Apotex Corp.; Hetero Labs Limited, Hetero Labs Limited Unit-V, Hetero Drugs Limited, Hetero USA, Inc. (collectively, “Hetero”); Eugia Pharma Specialities Limited (“Eugia Pharma”) and Aurobindo Pharma Ltd.; Mylan Pharmaceuticals Inc.; and Breckenridge Pharmaceutical, Inc. (“Breckenridge”) notifying Celgene that they had filed aNDAs containing paragraph IV certifications seeking approval to market generic versions of Pomalyst in the U.S. In response, Celgene filed patent infringement actions against the companies in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents and the companies filed answers, counterclaims and declaratory judgment actions alleging that the asserted patents are invalid, unenforceable and not infringed. These litigations were subsequently consolidated. In March 2020, Celgene subsequently filed additional patent infringement actions in the U.S. District Court for the District of New Jersey against each of the companies asserting a newly-issued patent that is listed in the FDA Orange Book and that covers formulations comprising pomalidomide. The companies each filed responsive pleadings between April and June 2020, alleging that the patent is invalid and not infringed. The Court has consolidated these additional litigations with the previously-consolidated litigations. In September 2020, the Court granted Mylan Pharmaceuticals Inc.’s motion to dismiss. In November 2020, Breckenridge and Eugia Pharma received final approval from the FDA of their respective aNDAs. A trial concerning the consolidated litigations is scheduled to begin on January 11, 2021, but is expected to be delayed. In February and March 2019, Celgene filed additional patent infringement actions in the U.S. District Court for the District of New Jersey against the companies asserting certain patents that are not listed in the FDA Orange Book and that cover polymorphic forms of pomalidomide, and the companies filed answer and/or counterclaims alleging that each of these patents is invalid and/or not infringed. In these actions, the Court has ordered that the parties be ready for trial by April 15, 2021. In June 2019, Celgene received a Notice Letter from Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (together, “DRL”) notifying Celgene that they had filed an aNDA containing paragraph IV certifications seeking approval to market a generic version of Pomalyst in the U.S. In response, Celgene initiated a patent infringement action against DRL in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents, and DRL filed an answer and counterclaims alleging that each of the patents is invalid and/or not infringed. In March 2020, Celgene filed an additional patent infringement action in the U.S. District Court for the District of New Jersey against DRL asserting a newly-issued patent that is listed in the FDA Orange Book and that covers formulations comprising pomalidomide, which has been consolidated with the above DRL case. The Court has not set a trial date in this consolidated action. Revlimid - U.S. Celgene has received Notice Letters on behalf of DRL; Zydus Pharmaceuticals (USA) Inc.; Cipla Ltd. (“Cipla”); Apotex; Sun Pharma Global FZE, Sun Pharma Global Inc., Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited; Hetero; Mylan Pharmaceuticals Inc., Mylan Inc., and Mylan N.V. (collectively, “Mylan”); Aurobindo Pharma Limited, Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Aurolife Pharma LLC; and Lupin Limited notifying Celgene that they had filed aNDAs containing paragraph IV certifications seeking approval to market generic versions of Revlimid in the U.S. In response, Celgene filed patent infringement actions against the companies in the U.S. District Court for the District of New Jersey asserting certain FDA Orange Book-listed patents as well as other litigations asserting other non-FDA Orange Book-listed patents against certain defendants, who have filed answers and/or counterclaims alleging that the asserted patents are invalid and/or not infringed. Mylan has filed a motion to dismiss the District of New Jersey action, and the Court stayed the action pending resolution of a pending Federal Circuit appeal in another case. No trial date has been scheduled in any of these New Jersey actions. Celgene also filed a patent infringement action against Mylan in the U.S. District Court for the Northern District of West Virginia (the “West Virginia action”) asserting certain FDA Orange Book-listed patents. Mylan filed its answer and counterclaims alleging that the patents are invalid and/or not infringed. A trial is scheduled to begin in the West Virginia action on October 4, 2021. On September 16, 2020, Celgene settled all outstanding claims in the litigation with DRL. Pursuant to the settlement, Celgene has agreed to provide DRL with a license to Celgene’s patents required to manufacture and sell certain volume-limited amounts of generic lenalidomide in the United States beginning on a certain date after the March 2022 volume-limited license date previously provided to Natco. In addition, Celgene has agreed to provide DRL with a license to Celgene’s patents required to manufacture and sell an unlimited quantity of generic lenalidomide in the United States beginning no earlier than January 31, 2026. Sprycel - U.S. In August 2019, BMS received a Notice Letter from Dr. Reddy’s Laboratories, Inc. notifying BMS that it had filed an aNDA containing paragraph IV certifications seeking approval of a generic version of Sprycel in the U.S. and challenging two FDA Orange Book-listed monohydrate form patents expiring in 2025 and 2026. In response, BMS filed a patent infringement action in the U.S. District Court for the District of New Jersey. No trial date has been scheduled. In March 2020, BMS received a Notice Letter from Teva notifying BMS that it had filed an aNDA containing paragraph IV certifications seeking approval of a generic version of Sprycel in the U.S. and challenging an FDA Orange Book-listed monohydrate form patent expiring in 2026. In response, BMS filed a patent infringement lawsuit in the U.S. District Court for the District of New Jersey. BMS and Teva settled and the case was dismissed. In May 2020, BMS received a Notice Letter from Lupin notifying BMS that it had filed an aNDA containing paragraph IV certifications seeking approval of a generic version of Sprycel in the U.S. and challenging two FDA Orange Book-listed monohydrate form patents expiring in 2025 and 2026. In response, BMS filed patent infringement actions in the U.S. District Courts for the District of New Jersey and Delaware. No trial date has been scheduled. PRICING, SALES AND PROMOTIONAL PRACTICES LITIGATION Plavix* State Attorneys General Lawsuits BMS and certain Sanofi entities are defendants in consumer protection and/or false advertising actions brought by the attorneys general of Hawaii and New Mexico relating to the sales and promotion of Plavix* . In the Hawaii matter, trial began on October 26, 2020 and is expected to last until mid-November. PRODUCT LIABILITY LITIGATION BMS is a party to various product liability lawsuits. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. As previously disclosed, in addition to lawsuits, BMS also faces unfiled claims involving its products. Abilify* BMS and Otsuka are co-defendants in product liability litigation related to Abilify* . Plaintiffs allege Abilify* caused them to engage in compulsive gambling and other impulse control disorders. There have been over 2,500 cases filed in state and federal courts and additional cases are pending in Canada. The Judicial Panel on Multidistrict Litigation consolidated the federal court cases for pretrial purposes in the U.S. District Court for the Northern District of Florida. In February 2019, BMS and Otsuka entered into a master settlement agreement establishing a proposed settlement program to resolve all Abilify* compulsivity claims filed as of January 28, 2019 in the MDL as well as various state courts, including California and New Jersey. To date, approximately 2,700 cases, comprising approximately 3,900 plaintiffs, have been dismissed based on participation in the settlement program or failure to comply with settlement related court orders. In the U.S., approximately 30 cases remain pending on behalf of plaintiffs, who either chose not to participate in the settlement program or filed their claims after the settlement cut-off date. There are ten cases pending in Canada (four class actions, six individual injury claims). Out of the ten cases, only three are active (the class actions in Quebec and Ontario and one individual injury claim). Both class actions have now been certified and will proceed separately. Byetta* Amylin, a former subsidiary of BMS, and Lilly are co-defendants in product liability litigation related to Byetta*. As of September 2020, there are approximately 590 separate lawsuits pending on behalf of approximately 2,250 active plaintiffs (including pending settlements), which include injury plaintiffs as well as claims by spouses and/or other beneficiaries, in various courts in the U.S. The majority of these cases have been brought by individuals who allege personal injury sustained after using Byetta *, primarily pancreatic cancer, and, in some cases, claiming alleged wrongful death. The majority of cases are pending in federal court in San Diego in an MDL or in a coordinated proceeding in California Superior Court in Los Angeles (“JCCP”). In November 2015, the defendants’ motion for summary judgment based on federal preemption was granted in both the MDL and the JCCP. In November 2017, the Ninth Circuit reversed the MDL summary judgment order and remanded the case to the MDL. In November 2018, the California Court of Appeal reversed the state court summary judgment order and remanded those cases to the JCCP for further proceedings. Amylin has filed a motion for summary judgment based on federal preemption and a motion for summary judgment based on the absence of general causation evidence, both were heard in October 2020. Amylin had product liability insurance covering a substantial number of claims involving Byetta* (which has been exhausted). As part of BMS’s global diabetes business divestiture, BMS sold Byetta* to AstraZeneca in February 2014 and any additional liability to Amylin with respect to Byetta* is expected to be shared with AstraZeneca. Onglyza* BMS and AstraZeneca are co-defendants in product liability litigation related to Onglyza* . Plaintiffs assert claims, including claims for wrongful death, as a result of heart failure or other cardiovascular injuries they allege were caused by their use of Onglyza* . As of September 2020, claims are pending in state and federal court on behalf of approximately 280 individuals who allege they ingested the product and suffered an injury. In February 2018, the Judicial Panel on Multidistrict Litigation ordered all federal cases to be transferred to an MDL in the U.S. District Court for the Eastern District of Kentucky. A significant majority of the claims are pending in the MDL. As part of BMS’s global diabetes business divestiture, BMS sold Onglyza* to AstraZeneca in February 2014 and any potential liability with respect to Onglyza* is expected to be shared with AstraZeneca. SECURITIES LITIGATION BMS Securities Class Action Since February 2018, two separate putative class action complaints were filed in the U.S. District for the Northern District of California and in the U.S. District Court for the Southern District of New York against BMS, BMS’s Chief Executive Officer, Giovanni Caforio, BMS’s Chief Financial Officer at the time, Charles A. Bancroft and certain former and current executives of BMS. The case in California has been voluntarily dismissed. The remaining complaint alleges violations of securities laws for BMS’s disclosures related to the CheckMate-026 clinical trial in lung cancer. In September 2019, the Court granted BMS’s motion to dismiss, but allowed the plaintiffs leave to file an amended complaint. In October 2019, the plaintiffs filed an amended complaint. BMS moved to dismiss the amended complaint. In September 2020, the Court granted BMS’s motion to dismiss with prejudice. The plaintiffs appealed the Court’s decision in October 2020. Celgene Securities Class Action Beginning in March 2018, two putative class actions were filed against Celgene and certain of its officers in the U.S. District Court for the District of New Jersey (the “Celgene Securities Class Action”). The complaints allege that the defendants violated federal securities laws by making misstatements and/or omissions concerning (1) trials of GED-0301, (2) Celgene’s 2020 outlook and projected sales of Otezla , and (3) the new drug application for Zeposia . The Court consolidated the two actions and appointed a lead plaintiff, lead counsel, and co-liaison counsel for the putative class. In February 2019, the defendants filed a motion to dismiss plaintiff’s amended complaint in full. In December 2019, the Court denied the motion to dismiss in part and granted the motion to dismiss in part (including all claims arising from alleged misstatements regarding GED-0301). Although the Court gave the plaintiff leave to re-plead the dismissed claims, it elected not to do so, and the dismissed claims are now dismissed with prejudice. No trial date has been scheduled for the claims that survived the Court’s order. In May 2020, the plaintiff filed a motion for class certification. In June 2020, the defendants filed an opposition to the plaintiff’s motion for class certification. In April 2020, certain Schwab management investment companies on behalf of certain Schwab funds filed an individual action in the U.S. District Court for the District of New Jersey asserting largely the same allegations as the Celgene Securities Class Action against the same remaining defendants in that action. In July 2020, the defendants filed a motion to dismiss the plaintiffs’ complaint in full. OTHER LITIGATION Average Manufacturer Price Litigation BMS is a defendant in a qui tam (whistleblower) lawsuit in the U.S. District Court for the Eastern District of Pennsylvania, in which the U.S. Government declined to intervene. The complaint alleges that BMS inaccurately reported its average manufacturer prices to the Centers for Medicare and Medicaid Services to lower what it owed. Similar claims have been filed against other companies. In January 2020, BMS reached an agreement in principle to resolve this matter subject to the negotiation of a definitive settlement agreement and other contingencies. BMS cannot provide assurances that its efforts to reach a final settlement will be successful. HIV Medication Antitrust Lawsuits BMS and several other manufacturers of HIV medications are defendants in related lawsuits pending in the Northern District of California. The lawsuits allege that the defendants’ agreements to develop and sell fixed-dose combination products for the treatment of HIV, including Atripla* and Evotaz , violate antitrust laws. The currently pending actions, which are asserted on behalf of indirect purchasers, were initiated in 2019 in the Northern District of California and in 2020 in the Southern District of Florida. The Florida matter was transferred to the Northern District of California. In July 2020, the Court granted in part defendants’ motion to dismiss, including dismissing with prejudice plaintiffs’ claims as to an overarching conspiracy and plaintiffs' theories based on the alleged payment of royalties after patent expiration. Other claims, however, remain. A trial is scheduled for February 2022. In addition, two actions on behalf of direct purchasers were filed in September and October 2020 in the Northern District of California asserting similar claims. Humana Litigations On May 16, 2018, Humana, Inc. (“Humana”) filed a lawsuit against Celgene in the Pike County Circuit Court of the Commonwealth of Kentucky. Humana’s complaint alleges Celgene engaged in unlawful off-label marketing in connection with sales of Thalomid and Revlimid and asserts claims against Celgene for fraud, breach of contract, negligent misrepresentation, unjust enrichment and violations of New Jersey’s Racketeer Influenced and Corrupt Organizations Act. The complaint seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. In April 2019, Celgene filed a motion to dismiss Humana’s complaint, which the Court denied in January 2020. No trial date has been scheduled. In May 2020, Celgene filed suit against Humana Pharmacy, Inc. (“HPI”), a Humana subsidiary, in Delaware Superior Court. Celgene’s complaint alleges that HPI breached its contractual obligations to Celgene by assigning claims to Humana that Humana is now asserting. The complaint seeks damages for HPI’s breach as well as a declaratory judgment. In September 2020, HPI filed a motion to dismiss Celgene’s complaint. On March 1, 2019, Humana filed a separate lawsuit against Celgene in the U.S. District Court for the District of New Jersey. Humana’s complaint alleges that Celgene violated various antitrust, consumer protection, and unfair competition laws to delay or prevent generic competition for Thalomid and Revlimid brand drugs, including (a) allegedly refusing to sell samples of products to generic manufacturers for purposes of bioequivalence testing intended to be included in aNDAs for approval to market generic versions of these products; (b) allegedly bringing unjustified patent infringement lawsuits, procuring invalid patents, and/or entering into anticompetitive patent settlements; (c) allegedly securing an exclusive supply contract for supply of thalidomide active pharmaceutical ingredient. The complaint purports to assert claims on behalf of Humana and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. Celgene filed a motion to dismiss Humana’s complaint, and the Court has stayed discovery pending adjudication of that motion. No trial date has been scheduled. Thalomid and Revlimid Antitrust Class Action Litigation and Related Proceedings Beginning in November 2014, certain putative class action lawsuits were filed against Celgene in the U.S. District Court for the District of New Jersey alleging that Celgene violated various antitrust, consumer protection, and unfair competition laws by (a) allegedly securing an exclusive supply contract for the alleged purpose of preventing a generic manufacturer from securing its own supply of thalidomide active pharmaceutical ingredient, (b) allegedly refusing to sell samples of Thalomid and Revlimid brand drugs to various generic manufacturers for the alleged purpose of bioequivalence testing necessary for aNDAs to be submitted to the FDA for approval to market generic versions of these products, (c) allegedly bringing unjustified patent infringement lawsuits in order to allegedly delay approval for proposed generic versions of Thalomid and Revlimid , and/or (d) allegedly entering into settlements of patent infringement lawsuits with certain generic manufacturers that allegedly have had anticompetitive effects. The plaintiffs, on behalf of themselves and putative classes of third-party payers, are seeking injunctive relief and damages. The various lawsuits were consolidated into a master action for all purposes. In October 2017, the plaintiffs filed a motion for certification of two damages classes under the laws of thirteen states and the District of Columbia and a nationwide injunction class. Celgene filed an opposition to the plaintiffs’ motion and a motion for judgment on the pleadings dismissing all state law claims where the plaintiffs no longer seek to represent a class. In October 2018, the Court denied the plaintiffs’ motion for class certification and Celgene’s motion for judgment on the pleadings. In December 2018, the plaintiffs filed a new motion for class certification, which Celgene opposed. In July 2019, the parties reached a settlement under which all the putative class plaintiff claims would be dismissed with prejudice. In December 2019, after certain third-party payors who were members of the settlement class refused to release their potential claims and participate in the settlement, Celgene exercised its right to terminate the settlement agreement. In March 2020, Celgene reached a revised settlement with the class plaintiffs. In May 2020, the Court preliminarily approved the settlement. In October 2020, the Court entered a final order approving the settlement and dismissed the matter. That settlement does not resolve the claims of certain entities that opted out of the first settlement. In March 2020, United HealthCare Services, Inc. (“UHS”), affiliates of which opted out of the first settlement in the Thalomid and Revlimid Antitrust Class Action Litigation, filed a lawsuit against Celgene in the U.S. District Court for the District of Minnesota. UHS’s complaint makes largely the same claims and allegations as the class action litigation. The complaint purports to assert claims on behalf of UHS and its subsidiaries in several capacities, including as a direct purchaser and as an indirect purchaser, and seeks, among other things, treble and punitive damages, injunctive relief and attorneys’ fees and costs. Motions to transfer and dismiss this matter are pending. In July 2020, Blue Cross Blue Shield Association (“BCBSA”) sued Celgene and BMS on behalf of the Federal Employee Program in the U.S. District Court for the District of Columbia. BCBSA’s complaint makes largely the same claims and allegations as the class action litigation. A motion to transfe

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)9 Months Ended
Sep. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Consolidation, Policy [Policy Text Block]Basis of Consolidation Bristol-Myers Squibb Company prepared these unaudited consolidated financial statements following the requirements of the SEC and U.S. GAAP for interim reporting. Under those rules, certain footnotes and other financial information that are normally required for annual financial statements can be condensed or omitted. The Company is responsible for the consolidated financial statements included in this Quarterly Report on Form 10-Q, which include all adjustments necessary for a fair presentation of the financial position at September 30, 2020 and December 31, 2019, the results of operations for the three and nine months ended September 30, 2020 and 2019, and cash flows for the nine months ended September 30, 2020 and 2019. All intercompany balances and transactions have been eliminated. BMS’s consolidated financial statements include the assets, liabilities, operating results and cash flows of Celgene from the date of acquisition on November 20, 2019. These financial statements and the related notes should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2019 included in the 2019 Form 10-K. Refer to the Summary of Abbreviated Terms at the end of this Quarterly Report on Form 10-Q for terms used throughout the document.
Segment Reporting, Policy [Policy Text Block]Business Segment Information BMS operates in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. A global research and development organization and supply chain organization are responsible for the discovery, development, manufacturing and supply of products. Regional commercial organizations market, distribute and sell the products. The business is also supported by global corporate staff functions. Consistent with BMS’s operational structure, the Chief Executive Officer (“CEO”), as the chief operating decision maker, manages and allocates resources at the global corporate level. Managing and allocating resources at the global corporate level enables the CEO to assess both the overall level of resources available and how to best deploy these resources across functions, therapeutic areas, regional commercial organizations and research and development projects in line with our overarching long-term corporate-wide strategic goals, rather than on a product or franchise basis. The determination of a single segment is consistent with the financial information regularly reviewed by the CEO for purposes of evaluating performance, allocating resources, setting incentive compensation targets, and planning and forecasting future periods. For further information on product and regional revenue, see “—Note 2. Revenue.”
Use of Estimates, Policy [Policy Text Block]Use of Estimates and Judgments Revenues, expenses, assets and liabilities can vary during each quarter of the year. Accordingly, the results and trends in these unaudited consolidated financial statements may not be indicative of full year operating results. The preparation of financial statements requires the use of management estimates, judgments and assumptions. The most significant assumptions are estimates used in determining accounting for business combinations; impairments of intangible assets; sales rebate and return accruals; legal contingencies; and income taxes. Actual results may differ from estimates.
Reclassification, Policy [Policy Text Block]Reclassifications Certain reclassifications were made to conform the prior period interim consolidated financial statements to the current period presentation.
New Accounting Pronouncements, Policy [Policy Text Block]Recently Adopted Accounting Standards Financial Instruments - Measurement of Credit Losses In June 2016, the FASB issued amended guidance for the measurement of credit losses on financial instruments. Entities are required to use a forward-looking estimated loss model. Available-for-sale debt security credit losses will be recognized as allowances rather than a reduction in amortized cost. BMS adopted the amended guidance on a modified retrospective approach on January 1, 2020. The amended guidance did not impact BMS’s results of operations.

Revenue Recognition (Tables)

Revenue Recognition (Tables)9 Months Ended
Sep. 30, 2020
Disaggregation of Revenue [Abstract]
Disaggregation of Revenue [Table Text Block]The following table summarizes the disaggregation of revenue by nature: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Net product sales $ 10,197 $ 5,768 $ 30,555 $ 17,512 Alliance revenues 184 143 452 418 Other revenues 159 96 443 270 Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200
Revenue Recognition Gross-To-Net Adjustments [Policy Text Block]The following table summarizes GTN adjustments: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Gross product sales $ 15,211 $ 8,884 $ 43,685 $ 25,697 GTN adjustments (a) Charge-backs and cash discounts (1,440) (927) (4,072) (2,591) Medicaid and Medicare rebates (2,146) (1,362) (5,126) (3,252) Other rebates, returns, discounts and adjustments (1,428) (827) (3,932) (2,342) Total GTN adjustments (5,014) (3,116) (13,130) (8,185) Net product sales $ 10,197 $ 5,768 $ 30,555 $ 17,512 (a) Includes adjustments for provisions for product sales made in prior periods resulting from changes in estimates of $(25) million and $91 million for the three and nine months ended September 30, 2020 and $12 million and $139 million for the three and nine months ended September 30, 2019, respectively.
Revenue from External Customers by Products and Services [Table Text Block]The following table summarizes the disaggregation of revenue by product and region: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Prioritized Brands Revlimid $ 3,027 $ — $ 8,826 $ — Eliquis 2,095 1,928 6,899 5,895 Opdivo 1,780 1,817 5,199 5,441 Orencia 826 767 2,290 2,185 Pomalyst/Imnovid 777 — 2,235 — Sprycel 544 558 1,576 1,561 Yervoy 446 353 1,211 1,104 Abraxane 342 — 950 — Empliciti 96 89 290 263 Reblozyl 96 — 159 — Inrebic 13 — 40 — Zeposia 2 — 3 — Onureg 3 — 3 — Established Brands Baraclude 100 145 343 433 Vidaza 106 — 390 — Other Brands (a) 287 350 1,036 1,318 Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200 United States $ 6,542 $ 3,472 $ 19,795 $ 10,588 Europe 2,453 1,445 7,156 4,416 Rest of the World 1,361 976 4,030 2,838 Other (b) 184 114 469 358 Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200 (a) Includes BMS and Celgene products in 2020. (b) Other revenues include royalties and alliance-related revenues for products not sold by BMS’s regional commercial organizations.

ALLIANCES (Tables)

ALLIANCES (Tables)9 Months Ended
Sep. 30, 2020
ALLIANCES [Abstract]
Collaborative Arrangement, Accounting Policy [Policy Text Block]BMS enters into collaboration arrangements with third parties for the development and commercialization of certain products. Although each of these arrangements is unique in nature, both parties are active participants in the operating activities of the collaboration and exposed to significant risks and rewards depending on the commercial success of the activities. BMS may either in-license intellectual property owned by the other party or out-license its intellectual property to the other party. These arrangements also typically include research, development, manufacturing, and/or commercial activities and can cover a single investigational compound or commercial product or multiple compounds and/or products in various life cycle stages. The rights and obligations of the parties can be global or limited to geographic regions. BMS refers to these collaborations as alliances and its partners as alliance partners.

ACQUISITIONS, DIVESTITURES AN_2

ACQUISITIONS, DIVESTITURES AND OTHER ARRANGEMENTS DIVESTITURES (Tables)9 Months Ended
Sep. 30, 2020
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Recognized Identified Assets Acquired and Liabilities AssumedDollars in Millions Amounts Recognized as of Acquisition Date Measurement Period Adjustments Amounts Recognized as of Acquisition Date Cash and cash equivalents $ 11,179 $ — $ 11,179 Receivables 2,652 — 2,652 Inventories 4,511 — 4,511 Property, plant and equipment 1,342 (277) 1,065 Intangible assets 64,027 (100) 63,927 Otezla* assets held-for-sale 13,400 — 13,400 Other assets 3,408 45 3,453 Accounts payable (363) — (363) Income taxes payable (2,718) (47) (2,765) Deferred income tax liabilities (7,339) 2,350 (4,989) Debt (21,782) — (21,782) Other liabilities (4,017) 15 (4,002) Identifiable net assets acquired 64,300 1,986 66,286 Goodwill 15,969 (1,986) 13,983 Total consideration transferred $ 80,269 $ — $ 80,269
Disposal Groups, Including Discontinued OperationsThe following table summarizes the financial impact of divestitures including royalties, which are included in Other (income)/expense, net. Revenue and pretax earnings related to all divestitures and assets held-for-sale were not material in all periods presented (excluding divestiture gains or losses). Three Months Ended September 30, Net Proceeds (a) Divestiture (Gains)/Losses Royalty and Milestone Income Dollars in Millions 2020 2019 2020 2019 2020 2019 UPSA Business $ — $ 1,510 $ — $ (1,176) $ — $ — Diabetes Business 129 163 — — (148) (171) Erbitux* 3 3 — — — — Manufacturing Operations — — — 1 — — Mature Brands and Other 41 7 1 (4) (44) (6) Total $ 173 $ 1,683 $ 1 $ (1,179) $ (192) $ (177) Nine Months Ended September 30, Net Proceeds (a) Divestiture (Gains)/Losses Royalty and Milestone Income Dollars in Millions 2020 2019 2020 2019 2020 2019 UPSA Business $ — $ 1,510 $ — $ (1,160) $ — $ — Diabetes Business 409 491 — — (404) (497) Erbitux* 10 11 — — — — Manufacturing Operations 10 3 (1) 1 — — Plavix* and Avapro*/Avalide* 7 — (12) — — — Mature Brands and Other 73 9 7 (12) (76) (8) Total $ 509 $ 2,024 $ (6) $ (1,171) $ (480) $ (505) (a) Includes royalties received subsequent to the related sale of the asset or business.
Licensing and Other ArrangementsThe following table summarizes the financial impact of Keytruda* royalties, up-front and milestone licensing fees for products that have not obtained commercial approval, which are included in Other (income)/expense, net. Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Keytruda * royalties $ (176) $ (132) $ (492) $ (373) Up-front licensing fees — (24) (30) (24) Contingent milestone income (16) (6) (62) (15) Amortization of deferred income (14) (14) (44) (44) Other royalties (5) (3) (16) (6) Total $ (211) $ (179) $ (644) $ (462)

OTHER EXPENSE (INCOME), NET (Ta

OTHER EXPENSE (INCOME), NET (Tables)9 Months Ended
Sep. 30, 2020
Other Nonoperating Income (Expense) [Abstract]
Schedule Of Other Income Expense [Table Text Block]Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Interest expense $ 346 $ 209 $ 1,065 $ 377 Pension and postretirement — 1,537 (6) 1,607 Royalties and licensing income (403) (356) (1,124) (967) Divestiture losses/(gains) 1 (1,179) (6) (1,171) Acquisition expenses — 7 — 475 Contingent consideration (988) — (597) — Investment income (13) (173) (99) (348) Integration expenses 195 96 535 224 Provision for restructuring 176 10 451 32 Equity investment (gains)/losses (244) 261 (724) 15 Litigation and other settlements 10 (1) 41 — Transition and other service fees (18) (7) (129) (11) Intangible asset impairment — — 21 15 Reversion excise tax — — 76 — Other 23 6 8 1 Other (income)/expense, net $ (915) $ 410 $ (488) $ 249

RESTRUCTURING (Tables)

RESTRUCTURING (Tables)9 Months Ended
Sep. 30, 2020
Celgene Integration [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]The following tables summarize the charges and activity related to the Celgene acquisition: Dollars in Millions Three Months Ended Nine Months Ended Employee termination costs $ 133 $ 386 Other termination costs 36 42 Provision for restructuring 169 428 Integration expenses 195 535 Accelerated depreciation 6 6 Asset impairments 3 42 Other — 3 Total charges $ 373 $ 1,014 Dollars in Millions Three Months Ended Nine Months Ended Marketing, selling and administrative $ 6 $ 7 Research and development 3 42 Other (income)/expense, net 364 965 Total charges $ 373 $ 1,014
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]Dollars in Millions Nine Months Ended Liability at January 1 $ 77 Charges 372 Change in estimates (8) Provision for restructuring (a) 364 Foreign currency translation and other 2 Payments (255) Liability at September 30 $ 188 (a) Excludes $64 million of accelerated stock-based compensation.
Operating Model 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Costs [Table Text Block]The following tables summarize the charges and activity related to the Company transformation: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Employee termination costs $ — $ 4 $ 3 $ 11 Other termination costs 7 6 20 21 Provision for restructuring 7 10 23 32 Accelerated depreciation 1 33 42 96 Asset impairments 2 9 44 119 Other shutdown costs — — 6 — Total charges $ 10 $ 52 $ 115 $ 247 Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Cost of products sold $ 3 $ 22 $ 30 $ 156 Marketing, selling and administrative — — — 1 Research and development — 20 56 58 Other (income)/expense, net 7 10 29 32 Total charges $ 10 $ 52 $ 115 $ 247
Schedule of Restructuring Reserve by Type of Cost [Table Text Block]Nine Months Ended September 30, Dollars in Millions 2020 2019 Liability at December 31 $ 23 $ 99 Cease-use liability reclassification — (3) Liability at January 1 23 96 Charges 22 36 Change in estimates 1 (4) Provision for restructuring 23 32 Foreign currency translation and other — (1) Payments (40) (98) Liability at September 30 $ 6 $ 29

INCOME TAXES (Tables)

INCOME TAXES (Tables)9 Months Ended
Sep. 30, 2020
Income Tax Disclosure [Abstract]
Schedule of Provision for Income Taxes [Table Text Block]Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Earnings Before Income Taxes $ 2,257 $ 1,349 $ 3,580 $ 5,104 Provision/(Benefit) for Income Taxes 379 (17) 2,548 584 Effective Tax Rate 16.8 % (1.3) % 71.2 % 11.4 %

EARNINGS PER SHARE (Tables)

EARNINGS PER SHARE (Tables)9 Months Ended
Sep. 30, 2020
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]Three Months Ended September 30, Nine Months Ended September 30, Amounts in Millions, Except Per Share Data 2020 2019 2020 2019 Net Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation $ 1,872 $ 1,353 $ 1,012 $ 4,495 Weighted-Average Common Shares Outstanding – Basic 2,257 1,632 2,260 1,634 Incremental Shares Attributable to Share-Based Compensation Plans 33 2 35 2 Weighted-Average Common Shares Outstanding – Diluted 2,290 1,634 2,295 1,636 Earnings per Common Share Basic $ 0.83 $ 0.83 $ 0.45 $ 2.75 Diluted 0.82 0.83 0.44 2.75

FINANCIAL INSTRUMENTS AND FAI_2

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)9 Months Ended
Sep. 30, 2020
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]Financial assets and liabilities measured at fair value on a recurring basis are summarized below: September 30, 2020 December 31, 2019 Dollars in Millions Level 1 Level 2 Level 3 Level 1 Level 2 Level 3 Cash and cash equivalents - money market and other securities $ — $ 17,075 $ — $ — $ 10,448 $ — Marketable debt securities: Certificates of deposit — 1,391 — — 1,227 — Commercial paper — — — — 1,093 — Corporate debt securities — 824 — — 1,494 — Derivative assets — 74 — — 140 — Equity investments 2,927 134 — 2,020 175 — Derivative liabilities — (120) — — (40) — Contingent consideration liability: Contingent value rights 1,697 — — 2,275 — — Other acquisition related contingent consideration — — 73 — — 106
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]The fair value of our contingent consideration as of September 30, 2020 was calculated using the following significant unobservable inputs: Ranges (weighted average) utilized as of: Inputs September 30, 2020 Discount rate 2.2% to 2.7% (2.4%) Probability of payment 0% to 80% (2.7%) Projected year of payment for development and regulatory milestones 2021 to 2025
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]The following table represents a roll-forward of the fair value of level 3 instruments: Dollars in Millions Nine Months Ended September 30, 2020 Fair value as of January 1 $ 106 Changes in estimated fair value (35) Foreign exchange 2 Fair value as of September 30 $ 73
Available-for-sale Securities [Table Text Block]Changes in fair value of equity investments are included in Other (income)/expense, net. The following table summarizes available-for-sale debt securities and equity investments: September 30, 2020 December 31, 2019 Dollars in Millions Amortized Cost Gross Unrealized Amortized Cost Gross Unrealized Gains Losses Fair Value Gains Losses Fair Value Certificates of deposit $ 1,391 $ — $ — $ 1,391 $ 1,227 $ — $ — $ 1,227 Commercial paper — — — — 1,093 — — 1,093 Corporate debt securities 807 17 — 824 1,487 8 (1) 1,494 Total available-for-sale debt securities (a) $ 2,198 $ 17 $ — $ 2,215 $ 3,807 $ 8 $ (1) $ 3,814 Equity investments 3,061 2,195 Total $ 5,276 $ 6,009
Fair Value, Measured on Recurring Basis, Gain (Loss) Included in Earnings [Table Text Block]The following table summarizes the net gain/(loss) recorded for equity investments with readily determinable fair values held as of September 30, 2020 and 2019: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Net gain/(loss) recognized $ 170 $ (235) $ 577 $ (81) Less: Net gain recognized for equity investments sold — — — 14 Net unrealized gain/(loss) on equity investments held $ 170 $ (235) $ 577 $ (95)
Schedule of Derivatives and Fair Value [Table Text Block]The following table summarizes the fair value of outstanding derivatives: September 30, 2020 December 31, 2019 Asset (a) Liability (b) Asset (a) Liability (b) Dollars in Millions Notional Fair Value Notional Fair Value Notional Fair Value Notional Fair Value Derivatives designated as hedging instruments: Interest rate swap contracts $ 255 $ 27 $ — $ — $ 255 $ 6 $ — $ — Cross-currency interest rate swap contracts 225 2 175 (1) 175 2 125 (1) Foreign currency forward contracts 1,904 18 3,422 (116) 766 27 980 (20) Derivatives not designated as hedging instruments: Foreign currency forward contracts 1,108 27 478 (3) 2,342 91 1,173 (10) Foreign currency zero-cost collar contracts 123 — 65 — 2,482 14 2,235 (9) (a) Included in Other current assets and Other non-current assets. (b) Included in Other current liabilities and Other non-current liabilities.
Derivative Instruments, Gain (Loss) [Table Text Block]The following table summarizes the financial statement classification and amount of (gain)/loss recognized on hedging instruments: Three Months Ended September 30, 2020 Nine Months Ended September 30, 2020 Dollars in Millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Interest rate swap contracts $ — $ (7) $ — $ (21) Cross-currency interest rate swap contracts — (3) — (8) Foreign currency forward contracts (5) 14 (63) (41) Foreign currency zero-cost collar contracts — — — 1 Three Months Ended September 30, 2019 Nine Months Ended September 30, 2019 Dollars in Millions Cost of products sold Other (income)/expense, net Cost of products sold Other (income)/expense, net Interest rate swap contracts $ — $ (6) $ — $ (18) Cross-currency interest rate swap contracts — (2) — (6) Foreign currency forward contracts (20) (9) (76) (11) Forward starting interest rate swap options — — — 35 Deal contingent forward starting interest rate swap — — — 240
Gain/(Loss) on Hedging Activity [Table Text Block]The following table summarizes the effect of derivative and non-derivative instruments designated as hedging instruments in Other Comprehensive (Loss)/Income: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Derivatives qualifying as cash flow hedges Foreign currency forward contracts gain/(loss): Recognized in Other Comprehensive (Loss)/Income (a) $ (128) $ 63 $ (65) $ 102 Reclassified to Cost of products sold (17) (20) (69) (76) Derivatives qualifying as net investment hedges Cross-currency interest rate swap contracts gain/(loss): Recognized in Other Comprehensive (Loss)/Income (11) 2 (1) 4 Non-derivatives qualifying as net investment hedges Non-U.S. dollar borrowings gain/(loss): Recognized in Other Comprehensive (Loss)/Income (39) 41 (51) 43 (a) The amount is expected to be reclassified into earnings in the next 12 months.
Schedule of Short-term Debt [Table Text Block]Short-term debt obligations include: Dollars in Millions September 30, December 31, Non-U.S. short-term borrowings $ 183 $ 351 Current portion of long-term debt 3,250 2,763 Other 152 232 Total $ 3,585 $ 3,346
Schedule of Fair Value and Other Adjustments to Long Term Debt [Table Text Block]Long-term debt and the current portion of long-term debt include: Dollars in Millions September 30, December 31, Principal Value $ 42,896 $ 44,335 Adjustments to Principal Value: Fair value of interest rate swap contracts 27 6 Unamortized basis adjustment from swap terminations 155 175 Unamortized bond discounts and issuance costs (256) (280) Unamortized purchase price adjustments of Celgene debt 1,792 1,914 Total $ 44,614 $ 46,150 Current portion of long-term debt $ 3,250 $ 2,763 Long-term debt 41,364 43,387 Total $ 44,614 $ 46,150

RECEIVABLES (Tables)

RECEIVABLES (Tables)9 Months Ended
Sep. 30, 2020
Accounts Receivable, after Allowance for Credit Loss [Abstract]
Schedule Of Receivables [Table Text Block]Dollars in Millions September 30, December 31, Trade receivables $ 7,168 $ 6,888 Less charge-backs and cash discounts (371) (391) Less allowance for expected credit loss (20) (21) Net trade receivables 6,777 6,476 Alliance, royalties, VAT and other 1,285 1,209 Receivables $ 8,062 $ 7,685

INVENTORIES (Tables)

INVENTORIES (Tables)9 Months Ended
Sep. 30, 2020
Inventory, Net [Abstract]
Inventories [Table Text Block]Dollars in Millions September 30, December 31, Finished goods $ 822 $ 2,227 Work in process 2,069 3,267 Raw and packaging materials 221 172 Total inventories $ 3,112 $ 5,666 Inventories $ 1,949 $ 4,293 Other non-current assets 1,163 1,373

PROPERTY, PLANT AND EQUIPMENT (

PROPERTY, PLANT AND EQUIPMENT (Tables)9 Months Ended
Sep. 30, 2020
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]Dollars in Millions September 30, December 31, Land $ 188 $ 187 Buildings 5,708 6,336 Machinery, equipment and fixtures 3,101 3,157 Construction in progress 409 527 Gross property, plant and equipment 9,406 10,207 Less accumulated depreciation (3,666) (3,955) Property, plant and equipment (a) $ 5,740 $ 6,252

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)9 Months Ended
Sep. 30, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule Of Intangible Assets By Major Class [Table Text Block]Dollars in Millions Estimated Useful Lives September 30, December 31, Goodwill (a) $ 20,517 $ 22,488 Other intangible assets: Licenses 5 – 15 years 461 482 Acquired developed product rights (a) 3 – 15 years 59,651 46,827 Capitalized software 3 – 10 years 1,357 1,297 IPRD 6,600 19,500 Gross other intangible assets 68,069 68,106 Less accumulated amortization (11,371) (4,137) Other intangible assets $ 56,698 $ 63,969 (a) Includes measurement period adjustments. Refer to “—Note 4. Acquisitions, Divestitures, Licensing and Other Arrangements” for more information.

Supplemental Financial Inform_2

Supplemental Financial Information (Tables)9 Months Ended
Sep. 30, 2020
Supplemental Financial Information [Abstract]
Schedule of Other Current Assets [Table Text Block]Dollars in Millions September 30, December 31, 2019 Prepaid and refundable income taxes $ 1,633 $ 754 Research and development 462 410 Equity investments 126 — Other (a) 890 819 Other current assets $ 3,111 $ 1,983
Schedule of Other Assets, Noncurrent [Table Text Block]Dollars in Millions September 30, December 31, 2019 Equity investments $ 4,166 $ 3,405 Inventories 1,163 1,373 Operating leases 718 704 Pension and postretirement 222 456 Restricted cash (a) 341 390 Other 286 276 Other non-current assets $ 6,896 $ 6,604 (a) Restricted cash consists of escrow for litigation settlements and funds restricted for annual Company contributions to the defined contribution plan in the U.S. Restricted cash of $425 million was included in cash, cash equivalents and restricted cash at September 30, 2020 in the consolidated statements of cash flows.
Schedule of Accrued Liabilities [Table Text Block]Dollars in Millions September 30, December 31, 2019 Rebates and returns $ 5,747 $ 4,275 Income taxes payable 686 1,517 Employee compensation and benefits 1,069 1,457 Research and development 1,315 1,324 Dividends 1,043 1,025 Interest 380 493 Royalties 398 418 Operating leases 136 133 Contingent value rights 1,680 — Other 1,984 1,871 Other current liabilities $ 14,438 $ 12,513
Other Noncurrent Liabilities [Table Text Block]Dollars in Millions September 30, December 31, 2019 Income taxes payable $ 5,025 $ 5,368 Contingent value rights 17 2,275 Pension and postretirement 871 725 Operating leases 722 672 Deferred income 361 424 Deferred compensation 301 287 Other 268 350 Other non-current liabilities $ 7,565 $ 10,101

EQUITY (Tables)

EQUITY (Tables)9 Months Ended
Sep. 30, 2020
Equity [Abstract]
Schedule of Stock by Class [Table Text Block]The following table summarizes changes in equity for the nine months ended September 30, 2020: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and Shares in Millions Shares Par Value Shares Cost Balance at December 31, 2019 2,923 $ 292 $ 43,709 $ (1,520) $ 34,474 672 $ (25,357) $ 100 Net loss — — — — (775) — — 9 Other Comprehensive Loss — — — (29) — — — — Cash dividends declared (a) — — — — (1,028) — — — Share repurchase program — — — — — 1 (81) — Stock compensation — — (455) — — (13) 681 — Distributions — — — — — — — (43) Balance at March 31, 2020 2,923 292 43,254 (1,549) 32,671 660 (24,757) 66 Net loss — — — — (85) — — 5 Other Comprehensive Loss — — — (7) — — — — Cash dividends declared (a) — — — — (1,021) — — — Stock repurchase program — — 1,400 — — 16 (1,400) — Stock compensation — — (210) — — (7) 506 — Distributions — — — — — — — (5) Balance at June 30, 2020 2,923 292 44,444 (1,556) 31,565 669 (25,651) 66 Net earnings — — — — 1,872 — — 6 Other Comprehensive Loss — — — (143) — — — — Cash dividends declared (a) — — — — (1,023) — — — Stock repurchase program — — — — — — — — Stock compensation — — (9) — — (6) 367 — Distributions — — — — — — — — Balance at September 30, 2020 2,923 $ 292 $ 44,435 $ (1,699) $ 32,414 663 $ (25,284) $ 72 (a) Cash dividends declared per common share were $0.45 for the three months ended March 31, 2020, June 30, 2020 and September 30, 2020. The following table summarizes changes in equity for the nine months ended September 30, 2019: Common Stock Capital in Excess of Par Value of Stock Accumulated Other Comprehensive Loss Retained Earnings Treasury Stock Noncontrolling Interest Dollars and Shares in Millions Shares Par Value Shares Cost Balance at December 31, 2018 2,208 $ 221 $ 2,081 $ (2,762) $ 34,065 576 $ (19,574) $ 96 Accounting change - cumulative effect (a) — — — — 5 — — — Adjusted balance at January 1, 2019 2,208 221 2,081 (2,762) 34,070 576 (19,574) 96 Net earnings — — — — 1,710 — — 5 Other Comprehensive Income — — — 118 — — — — Cash dividends declared (b) — — — — (671) — — — Stock compensation — — 22 — — (4) 3 — Distributions — — — — — — — (2) Balance at March 31, 2019 2,208 221 2,103 (2,644) 35,109 572 (19,571) 99 Net earnings — — — — 1,432 — — 7 Other Comprehensive Income — — — 23 — — — — Cash dividends declared (b) — — — — (671) — — — Stock compensation — — 47 — — — — — Distributions — — — — — — — (4) Balance at June 30, 2019 2,208 221 2,150 (2,621) 35,870 572 (19,571) 102 Net earnings — — — — 1,353 — — 13 Other Comprehensive Income — — — 1,158 — — — — Cash dividends declared (b) — — — — (668) — — — Stock repurchase program — — — — — 7 (300) — Stock compensation — — 56 — — — — — Distributions — — — — — — — (9) Balance at September 30, 2019 2,208 $ 221 $ 2,206 $ (1,463) $ 36,555 579 $ (19,871) $ 106 (a) Refer to “—Note 1. Accounting Policies and Recently Issued Accounting Standards” in the Company’s 2019 Form 10-K for additional information. (b) Cash dividends declared per common share were $0.41 for the three months ended March 31, 2019, June 30, 2019 and September 30, 2019.
Schedule of Comprehensive Income Loss [Table Text Block]The components of Other Comprehensive (Loss)/Income were as follows: 2020 2019 Dollars in Millions Pretax Tax After Tax Pretax Tax After Tax Three Months Ended September 30, Derivatives qualifying as cash flow hedges: Unrealized gain/(losses) $ (128) $ 10 $ (118) $ 63 $ (8) $ 55 Reclassified to net earnings (a) (17) 3 (14) (20) 3 (17) Derivatives qualifying as cash flow hedges (145) 13 (132) 43 (5) 38 Pension and postretirement benefits: Actuarial losses (16) 3 (13) (126) 27 (99) Amortization (b) 9 (2) 7 12 (2) 10 Settlements (b) 3 (1) 2 1,550 (345) 1,205 Pension and postretirement benefits (4) — (4) 1,436 (320) 1,116 Available-for-sale debt securities: Unrealized gains/(losses) (4) 2 (2) 6 (2) 4 Foreign currency translation (16) 11 (5) 10 (10) — Other Comprehensive (Loss)/Income $ (169) $ 26 $ (143) $ 1,495 $ (337) $ 1,158 Nine Months Ended September 30, Derivatives qualifying as cash flow hedges: Unrealized gains/(losses) $ (65) $ 4 $ (61) $ 102 $ (12) $ 90 Reclassified to net earnings (a) (69) 9 (60) (76) 10 (66) Derivatives qualifying as cash flow hedges (134) 13 (121) 26 (2) 24 Pension and postretirement benefits: Actuarial losses (28) 6 (22) (140) 30 (110) Amortization (b) 27 (5) 22 45 (8) 37 Settlements (b) 7 (2) 5 1,643 (366) 1,277 Pension and postretirement benefits 6 (1) 5 1,548 (344) 1,204 Available-for-sale securities: Unrealized gains 10 (2) 8 42 (2) 40 Realized gains/(losses) (1) — (1) 3 — 3 Available-for-sale securities 9 (2) 7 45 (2) 43 Foreign currency translation (81) 11 (70) 39 (11) 28 Total Other Comprehensive (Loss)/Income $ (200) $ 21 $ (179) $ 1,658 $ (359) $ 1,299 (a) Included in Cost of products sold. (b) Included in Other (income)/expense, net.
Schedule of Accumulated Other Comprehensive Income Loss [Table Text Block]The accumulated balances related to each component of Other Comprehensive (Loss)/Income, net of taxes, were as follows: Dollars in Millions September 30, December 31, Derivatives qualifying as cash flow hedges $ (102) $ 19 Pension and postretirement benefits (894) (899) Available-for-sale debt securities 13 6 Foreign currency translation (716) (646) Accumulated other comprehensive loss $ (1,699) $ (1,520)

PENSION AND POSTRETIREMENT BE_2

PENSION AND POSTRETIREMENT BENEFIT PLANS (Tables)9 Months Ended
Sep. 30, 2020
Retirement Benefits [Abstract]
Schedule of Net Benefit Costs [Table Text Block]The net periodic benefit cost of defined benefit pension plans includes: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Service cost – benefits earned during the year $ 12 $ 6 $ 36 $ 18 Interest cost on projected benefit obligation 11 20 30 101 Expected return on plan assets (26) (39) (73) (173) Amortization of prior service credits (1) (1) (3) (3) Amortization of net actuarial loss 12 14 33 49 Curtailments and settlements 3 1,550 7 1,643 Net periodic pension benefit cost $ 11 $ 1,550 $ 30 $ 1,635

EMPLOYEE STOCK BENEFIT PLANS _2

EMPLOYEE STOCK BENEFIT PLANS Employee Stock Benefit Plans (Tables)9 Months Ended
Sep. 30, 2020
Share-based Payment Arrangement, Disclosure [Abstract]
Share-based Payment Arrangement, Cost by Plan [Table Text Block]Stock-based compensation expense was as follows: Three Months Ended September 30, Nine Months Ended September 30, Dollars in Millions 2020 2019 2020 2019 Cost of products sold $ 9 $ 4 $ 28 $ 11 Marketing, selling and administrative 81 32 255 90 Research and development 78 20 261 56 Other (income)/expense, net 17 — 64 — Total stock-based compensation expense $ 185 $ 56 $ 608 $ 157 Income tax benefit (a) $ 38 $ 10 $ 124 $ 29 (a) Income tax benefit excludes excess tax benefits from share-based compensation awards that were vested or exercised of $1 million and $29 million for the three and nine months ended September 30, 2020 and was not material for the three and nine months ended September 30, 2019.
Schedule Of Share Based Compensation Additional Information [Table Text Block]The number of units granted and the weighted-average fair value on the grant date for the nine months ended September 30, 2020 were as follows: Units in Millions Units Weighted-Average Fair Value Restricted stock units 13.0 $ 53.62 Market share units 0.9 53.92 Performance share units 1.4 55.61
Share-based Payment Arrangement, Nonvested Award, Cost [Table Text Block]Dollars in Millions Stock Options Restricted Stock Units Market Share Units Performance Share Units Unrecognized compensation cost $ 54 $ 991 $ 53 $ 93 Expected weighted-average period in years of compensation cost to be recognized 1.5 2.6 3.0 1.8

REVENUE RECOGNITION Revenue by

REVENUE RECOGNITION Revenue by Nature (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Disaggregation of Revenue [Line Items]
Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200
Net product sales [Member]
Disaggregation of Revenue [Line Items]
Total Revenues10,197 5,768 30,555 17,512
Other revenues [Member]
Disaggregation of Revenue [Line Items]
Total Revenues159 96 443 270
Collaborative Arrangement [Member]
Disaggregation of Revenue [Line Items]
Total Revenues2,300 2,607 7,492 7,830
Collaborative Arrangement [Member] | Net product sales [Member]
Disaggregation of Revenue [Line Items]
Total Revenues2,116 2,464 7,040 7,412
Collaborative Arrangement [Member] | Collaborative Arrangement [Member]
Disaggregation of Revenue [Line Items]
Total Revenues $ 184 $ 143 $ 452 $ 418

REVENUE RECOGNITION Gross-to-Ne

REVENUE RECOGNITION Gross-to-Net Adjustments (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Gross to Net Adjustments [Line Items]
Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200
Gross to Net Adjustments(5,014)(3,116)(13,130)(8,185)
Prior Period Gross to Net Adjustment Impacted by New Accounting Pronouncement(25)12 91 139
Sales Revenue, Gross [Member]
Gross to Net Adjustments [Line Items]
Total Revenues15,211 8,884 43,685 25,697
Net product sales [Member]
Gross to Net Adjustments [Line Items]
Total Revenues10,197 5,768 30,555 17,512
Charge-backs and cash discounts [Member]
Gross to Net Adjustments [Line Items]
Gross to Net Adjustments(1,440)(927)(4,072)(2,591)
Medicaid and Medicare rebates [Member]
Gross to Net Adjustments [Line Items]
Gross to Net Adjustments(2,146)(1,362)(5,126)(3,252)
Other rebates, returns, discounts and adjustments [Member]
Gross to Net Adjustments [Line Items]
Gross to Net Adjustments $ (1,428) $ (827) $ (3,932) $ (2,342)

REVENUE RECOGNITION Revenue b_2

REVENUE RECOGNITION Revenue by Product by Region (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Revenue from External Customer [Line Items]
Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200
Revlimid [Member]
Revenue from External Customer [Line Items]
Total Revenues3,027 0 8,826 0
Eliquis [Member]
Revenue from External Customer [Line Items]
Total Revenues2,095 1,928 6,899 5,895
Opdivo [Member]
Revenue from External Customer [Line Items]
Total Revenues1,780 1,817 5,199 5,441
Orencia [Member]
Revenue from External Customer [Line Items]
Total Revenues826 767 2,290 2,185
Pomalyst/Imnovid [Member]
Revenue from External Customer [Line Items]
Total Revenues777 0 2,235 0
Sprycel [Member]
Revenue from External Customer [Line Items]
Total Revenues544 558 1,576 1,561
Yervoy [Member]
Revenue from External Customer [Line Items]
Total Revenues446 353 1,211 1,104
Abraxane [Member]
Revenue from External Customer [Line Items]
Total Revenues342 0 950 0
Empliciti [Member]
Revenue from External Customer [Line Items]
Total Revenues96 89 290 263
Reblozyl [Member]
Revenue from External Customer [Line Items]
Total Revenues96 0 159 0
Inrebic [Member]
Revenue from External Customer [Line Items]
Total Revenues13 0 40 0
Zeposia
Revenue from External Customer [Line Items]
Total Revenues2 0 3 0
Baraclude [Member]
Revenue from External Customer [Line Items]
Total Revenues100 145 343 433
Vidaza [Member]
Revenue from External Customer [Line Items]
Total Revenues106 0 390 0
Mature Products And All Other [Member]
Revenue from External Customer [Line Items]
Total Revenues287 350 1,036 1,318
Onureg
Revenue from External Customer [Line Items]
Total Revenues3 0 3 0
UNITED STATES
Revenue from External Customer [Line Items]
Total Revenues6,542 3,472 19,795 10,588
European Union [Member]
Revenue from External Customer [Line Items]
Total Revenues2,453 1,445 7,156 4,416
Rest Of World [Member]
Revenue from External Customer [Line Items]
Total Revenues1,361 976 4,030 2,838
Other Region [Member]
Revenue from External Customer [Line Items]
Total Revenues $ 184 $ 114 $ 469 $ 358

REVENUE RECOGNITION Narratives

REVENUE RECOGNITION Narratives (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Revenue, Performance Obligation [Abstract]
Contract with Customer, Performance Obligation Satisfied in Previous Period $ 32 $ 78 $ 260 $ 341

ALLIANCES (Details)

ALLIANCES (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Jun. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019
Alliance Statement [Line Items]
Total Revenues $ 10,540 $ 6,007 $ 31,450 $ 18,200
Cost of products sold[1]2,502 1,790 8,863 5,586
Other (income)/expense, net(915)410 (488)249
Receivables - from alliance partners8,062 8,062 $ 7,685
Accounts payable - to alliance partners2,441 2,441 2,445
Collaborative Arrangement [Member]
Alliance Statement [Line Items]
Total Revenues2,300 2,607 7,492 7,830
Cost of products sold1,007 1,017 3,363 3,116
Selling, General and Administrative Expense(25)(33)(103)(93)
Research and Development Expense48 11 327 32
Other (income)/expense, net(28)(15)(59)(45)
Receivables - from alliance partners336 336 347
Accounts payable - to alliance partners971 971 1,026
Deferred income from alliance392 392 $ 431
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member] | bluebird [Member]
Alliance Statement [Line Items]
Milestones and royalties buyout $ 200
Net product sales [Member]
Alliance Statement [Line Items]
Total Revenues10,197 5,768 30,555 17,512
Net product sales [Member] | Collaborative Arrangement [Member]
Alliance Statement [Line Items]
Total Revenues2,116 2,464 7,040 7,412
Collaborative Arrangement [Member] | Collaborative Arrangement [Member]
Alliance Statement [Line Items]
Total Revenues $ 184 $ 143 $ 452 $ 418
[1]Excludes amortization of acquired intangible assets

ACQUISITIONS (Details)

ACQUISITIONS (Details) - USD ($) $ / shares in Units, $ in Millions9 Months Ended
Sep. 30, 2020Oct. 05, 2020Dec. 31, 2019Nov. 20, 2019
Business Acquisition [Line Items]
Other assets $ 3,453 $ 3,408
Goodwill20,517 $ 22,488
Cormorant [Member]
Business Acquisition [Line Items]
Contingent and Regulatory Milestone Payments100
MyoKardia [Member] | Subsequent Event [Member]
Business Acquisition [Line Items]
Asset Acquisition Payment $ 13,100
Business Acquisition, Share Price $ 225
Forbius [Member]
Business Acquisition [Line Items]
Contingent and Regulatory Milestone Payments815
Asset Acquisition Payment185
Deferred Tax Assets, Net7
Celgene [Member]
Business Acquisition [Line Items]
Cash and cash equivalents11,179 11,179
Receivables2,652 2,652
Inventories4,511 4,511
Property, plant, and equipment1,065 1,342
Measurement period adjustments - Property, plant, and equipment(277)
Intangible assets63,927 64,027
Measurement period adjustments - Intangible assets(100)
Otezla assets held-for-sale13,400 13,400
Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Other Assets45
Accounts payable(363)(363)
Income taxes payable(2,765)(2,718)
Measurement period adjustments - Income taxes payable(47)
Deferred income tax liabilities(4,989)(7,339)
Measurement period adjustments - Deferred income tax liabilities2,350
Debt(21,782)(21,782)
Other liabilities(4,002)(4,017)
Measurement period adjustments - Other liabilities15
Identifiable net assets acquired66,286 64,300
Measurement period adjustments - Identifiable net assets acquired1,986
Goodwill13,983 15,969
Measurement period adjustments - Goodwill(1,986)
Total consideration transferred $ 80,269 $ 80,269

DIVESTITURES (Details)

DIVESTITURES (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested $ 173 $ 1,683 $ 509 $ 2,024
Divestiture losses/(gains)1 (1,179)(6)(1,171)
Royalty Income, Nonoperating(192)(177)(480)(505)
Anagni [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Tangible Asset Impairment Charges113
Diabetes business [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested129 163 409 491
Divestiture losses/(gains)0 0 0 0
Royalty Income, Nonoperating(148)(171)(404)(497)
Erbitux [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested3 3 10 11
Divestiture losses/(gains)0 0 0 0
Royalty Income, Nonoperating0 0 0 0
Manufacturing Facility [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested0 0 10 3
Divestiture losses/(gains)0 1 (1)1
Royalty Income, Nonoperating0 0 0 0
Avapro, Avalide, and Plavix [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested7 0
Divestiture losses/(gains)(12)0
Royalty Income, Nonoperating0 0
Other divestitures [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested41 7 73 9
Divestiture losses/(gains)1 (4)7 (12)
Royalty Income, Nonoperating(44)(6)(76)(8)
UPSA
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses, Net of Cash Divested0 1,510 0 1,510
Divestiture losses/(gains)0 (1,176)0 (1,160)
Royalty Income, Nonoperating $ 0 $ 0 $ 0 $ 0

OTHER ARRANGEMENTS (Details)

OTHER ARRANGEMENTS (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019Oct. 05, 2020
Licensing Arrangements [Line Items]
Amortization of Other Deferred Charges $ (14) $ (14) $ (44) $ (44)
Licensing and Other Arrangements Income(211)(179)(644)(462)
Royalty Income, Nonoperating(192)(177)(480)(505)
Up-front Licensing Fee0 (24)(30)(24)
Contingent and Regulatory Milestone Income(16)(6)(62)(15)
Other Royalties
Licensing Arrangements [Line Items]
Royalty Income, Nonoperating(5)(3)(16)(6)
Keytruda Royalties
Licensing Arrangements [Line Items]
Royalty Income, Nonoperating(176)(132)(492)(373)
Diabetes business [Member]
Licensing Arrangements [Line Items]
Royalty Income, Nonoperating $ (148) $ (171) $ (404) $ (497)
Dragonfly Therapeutics, Inc. [Member] | Subsequent Event [Member]
Licensing Arrangements [Line Items]
Contingent and Regulatory Milestone Payments $ 2,800
License and Other Arrangements Upfront Payments $ 400

OTHER EXPENSE (INCOME), NET (De

OTHER EXPENSE (INCOME), NET (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Jun. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Other Nonoperating Income (Expense) [Abstract]
Interest expense $ 346 $ 209 $ 1,065 $ 377
Pension and postretirement0 1,537 (6)1,607
Royalties and licensing income(403)(356)(1,124)(967)
Divestiture losses/(gains)1 (1,179)(6)(1,171)
Acquisition expenses0 7 0 475
Contingent consideration(988)0 (597)0
Investment income(13)(173)(99)(348)
Integration expenses195 96 535 224
Provision for restructuring176 10 451 32
Equity investment (gains)/losses(244)261 (724)15
Litigation and other settlements10 (1)41 0
Transition and other service fees(18)(7)(129)(11)
Intangible asset impairment0 0 21 15
Reversion excise tax0 $ 76 0 76 0
Other23 6 8 1
Other (income)/expense, net $ (915) $ 410 $ (488) $ 249

RESTRUCTURING NARRATIVE (Detail

RESTRUCTURING NARRATIVE (Details) $ in Billions9 Months Ended
Sep. 30, 2020USD ($)
Operating Model 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date $ 1.5
Operating Model 2020 [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost $ 1.5
Cash outlays percentage40.00%
Operating Model 2020 [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost $ 2
Cash outlays percentage50.00%
Celgene Integration [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date $ 1.7
Cash outlays $ 2.5
Restructuring and Related Cost, Number of Positions Eliminated1,400
Celgene Integration [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost $ 2.5
Celgene Integration [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost $ 3

RESTRUCTURING RESTRUCTURING AND

RESTRUCTURING RESTRUCTURING AND RELATED COSTS TABLE (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Restructuring Cost and Reserve [Line Items]
Provision for restructuring $ 176 $ 10 $ 451 $ 32
Integration expenses195 96 535 224
Operating Model 2020 [Member]
Restructuring Cost and Reserve [Line Items]
Employee termination costs0 4 3 11
Other termination costs7 6 20 21
Provision for restructuring7 10 23 32
Accelerated depreciation1 33 42 96
Asset impairment2 9 44 119
Other shutdown costs0 0 6 0
Total charges10 52 115 247
Operating Model 2020 [Member] | Cost of products sold [Member]
Restructuring Cost and Reserve [Line Items]
Total charges3 22 30 156
Operating Model 2020 [Member] | Marketing, selling and administrative [Member]
Restructuring Cost and Reserve [Line Items]
Total charges0 0 0 1
Operating Model 2020 [Member] | Research and development [Member]
Restructuring Cost and Reserve [Line Items]
Total charges0 20 56 58
Operating Model 2020 [Member] | Other (income)/expense,net [Member]
Restructuring Cost and Reserve [Line Items]
Total charges7 $ 10 29 $ 32
Celgene Integration [Member]
Restructuring Cost and Reserve [Line Items]
Employee termination costs133 386
Other termination costs36 42
Provision for restructuring169 428
Integration expenses195 535
Accelerated depreciation6 6
Asset impairment3 42
Other0 3
Total charges373 1,014
Celgene Integration [Member] | Marketing, selling and administrative [Member]
Restructuring Cost and Reserve [Line Items]
Total charges6 7
Celgene Integration [Member] | Research and development [Member]
Restructuring Cost and Reserve [Line Items]
Total charges3 42
Celgene Integration [Member] | Other (income)/expense,net [Member]
Restructuring Cost and Reserve [Line Items]
Total charges $ 364 $ 965

RESTRUCTURING SCHEDULE OF RESTR

RESTRUCTURING SCHEDULE OF RESTRUCTURING RESERVE (Details) - USD ($) $ in MillionsJan. 01, 2020Jan. 01, 2019Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019Dec. 31, 2018
Provision for restructuring $ 176 $ 10 $ 451 $ 32
Foreign currency translation and other0 (1)
Operating Model 2020 [Member]
Restructuring Liability $ 23 $ 96 6 29 6 29 $ 23 $ 99
Cease-use liability reclassification0 $ (3)
Charges22 36
Change in estimates1 (4)
Provision for restructuring7 $ 10 23 32
Payments(40) $ (98)
Celgene Integration [Member]
Restructuring Liability $ 77 188 188
Charges372
Change in estimates(8)
Restructuring Charges Exclude Accelerated Stock-Based Compensation364
Provision for restructuring $ 169 428
Foreign currency translation and other2
Payments(255)
Celgene Integration [Member] | Accelerated Stock Based Compensation [Member]
Provision for restructuring $ 64

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Income Tax Disclosure [Line Items]
Earnings Before Income Taxes $ 2,257 $ 1,349 $ 3,580 $ 5,104
Provision for Income Taxes $ 379 $ (17) $ 2,548 $ 584
Effective Tax Rate16.80%(1.30%)71.20%11.40%
Deferred income taxes $ 1,419 $ (536)
Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations $ 81
Effective Income Tax Rate Reconciliation, Other Adjustments, Percent31.30%
Otezla Divestiture [Member]
Income Tax Disclosure [Line Items]
Provision for Income Taxes $ 266
Internal Transfer of Product Rights [Member]
Income Tax Disclosure [Line Items]
Deferred income taxes853
Minimum [Member]
Income Tax Disclosure [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible350 $ 350
Maximum [Member]
Income Tax Disclosure [Line Items]
Decrease in Unrecognized Tax Benefits is Reasonably Possible $ 390 $ 390

EARNINGS PER SHARE (Details)

EARNINGS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Earnings Per Share [Abstract]
Net (Loss)/Earnings Attributable to BMS Used for Basic and Diluted EPS Calculation $ 1,872 $ 1,353 $ 1,012 $ 4,495
Weighted-average common shares outstanding - basic2,257 1,632 2,260 1,634
Incremental shares attributable to share-based compensation plans33 2 35 2
Weighted-average common shares outstanding - diluted2,290 1,634 2,295 1,636
Earnings Per Share, Basic $ 0.83 $ 0.83 $ 0.45 $ 2.75
Earnings Per Share, Diluted $ 0.82 $ 0.83 $ 0.44 $ 2.75
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount27 29

FINANCIAL INSTRUMENTS AND FAI_3

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Fair Value Measurement) (Details) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020USD ($)percentageyrSep. 30, 2019USD ($)Sep. 30, 2020USD ($)percentageyrSep. 30, 2019USD ($)Jan. 01, 2020USD ($)Dec. 31, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale $ 2,215 $ 2,215 $ 3,814
Equity Securities, FV-NI3,061 3,061 2,195
Contingent consideration fair value adjustments(988) $ 0 (597) $ 0
Debt Securities, Available-for-sale, Amortized Cost2,198 2,198 3,807
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax17 17 8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax0 0 (1)
Total securities5,276 5,276 6,009
Equity Securities without Readily Determinable Fair Value, Amount735 735 781
Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Annual Amount46 318
Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Annual Amount2 203
Equity Securities, FV-NI, Gain (Loss)170 (235)577 (81)
Equity Securities, FV-NI, Realized Gain (Loss)0 0 0 14
Equity Securities, FV-NI, Unrealized Gain (Loss)170 $ (235)577 $ (95)
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure0 0 0
Derivative asset0 0 0
Derivative Liability0 0 0
Contingent consideration fair value0 0 0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure17,075 17,075 10,448
Derivative asset74 74 140
Derivative Liability(120)(120)(40)
Contingent consideration fair value0 0 0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and Cash Equivalents, Fair Value Disclosure0 0 0
Derivative asset0 0 0
Derivative Liability0 0 0
Contingent consideration fair value73 73 $ 106 106
Contingent consideration fair value adjustments(35)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Due to Foreign Exchange, Liability2
Certificates of Deposit [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale1,391 1,391 1,227
Debt Securities, Available-for-sale, Amortized Cost1,391 1,391 1,227
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax0 0 0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax0 0 0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 0
Certificates of Deposit [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale1,391 1,391 1,227
Certificates of Deposit [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 0
Commercial Paper [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 1,093
Debt Securities, Available-for-sale, Amortized Cost0 0 1,093
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax0 0 0
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax0 0 0
Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 0
Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 1,093
Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 0
Corporate Debt Securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale824 824 1,494
Debt Securities, Available-for-sale, Amortized Cost807 807 1,487
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax17 17 8
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax0 0 (1)
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 0
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale824 824 1,494
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Securities, Available-for-sale0 0 0
Other Assets [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI2,927 2,927 2,020
Other Assets [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI134 134 175
Other Assets [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Securities, FV-NI0 0 0
Portion at Other than Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Equity Method Investments496 496 429
Contingent Value Rights [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration fair value1,697 1,697 2,275
Contingent Value Rights [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration fair value0 0 0
Contingent Value Rights [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration fair value $ 0 $ 0 $ 0
Probability of payment [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input | percentage0.800.80
Probability of payment [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input | percentage0.027 0.027
Probability of payment [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input | percentage0 0
Measurement Input, Discount Rate [Member] | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input | percentage0.027 0.027
Measurement Input, Discount Rate [Member] | Weighted Average [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input | percentage0.024 0.024
Measurement Input, Discount Rate [Member] | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Debt Instrument, Measurement Input | percentage0.022 0.022
Projected Year of Payments | Maximum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input [Extensible List] | yr2,025 2,025
Projected Year of Payments | Minimum [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Business Combination, Contingent Consideration, Liability, Measurement Input [Extensible List] | yr2,021 2,021

FINANCIAL INSTRUMENTS AND FAI_4

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Derivatives and Hedging) (Details) € in Millions, $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020USD ($)Sep. 30, 2019USD ($)Sep. 30, 2020USD ($)Sep. 30, 2019USD ($)Sep. 30, 2020EUR (€)Dec. 31, 2019USD ($)
Derivative [Line Items]
Debt Instrument, Face Amount $ 42,896 $ 42,896 $ 44,335
Derivative, Basis Spread on Variable Rate4.60%4.60%4.60%
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax $ (128) $ 63 $ (65) $ 102
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax(17)(20)(69)(76)
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax(16)10 (81)39
Designated as Hedging Instrument [Member]
Derivative [Line Items]
Debt Instrument, Face Amount1,100 1,100 € 950
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax(39)41 (51)43
Interest Rate Swap [Member]
Derivative [Line Items]
Derivative Liability27 27 6
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset27 27 6
Derivative Liability0 0 0
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount255 255 255
Interest Rate Swap [Member] | Designated as Hedging Instrument [Member] | Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount0 0 0
Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax(11)2 (1)4
Cross Currency Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset2 2 2
Derivative Liability(1)(1)(1)
Cross Currency Interest Rate Contract [Member] | Designated as Hedging Instrument [Member] | Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount225 225 175
Cross Currency Interest Rate Contract [Member] | Designated as Hedging Instrument [Member] | Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount175 175 125
Foreign Exchange Forward [Member]
Derivative [Line Items]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax(128)63 (65)102
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset18 18 27
Derivative Liability(116)(116)(20)
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member] | Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount1,904 1,904 766
Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member] | Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount3,422 3,422 980
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset27 27 91
Derivative Liability(3)(3)(10)
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member] | Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount1,108 1,108 2,342
Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member] | Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount478 478 1,173
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative asset0 0 14
Derivative Liability0 0 (9)
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member] | Assets [Member]
Derivative [Line Items]
Derivative, Notional Amount123 123 2,482
Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member] | Liability [Member]
Derivative [Line Items]
Derivative, Notional Amount65 65 $ 2,235
Forward Starting Interest Rate Swap Contracts [Member] | Not Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount10,400 10,400
Euro Member Countries, Euro | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount3,000 3,000
Japan, Yen | Cross Currency Interest Rate Contract [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount400 400
Japan, Yen | Foreign Exchange Forward [Member] | Designated as Hedging Instrument [Member]
Derivative [Line Items]
Derivative, Notional Amount1,400 1,400
Cost of products sold [Member] | Interest Rate Swap [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net0 0 0 0
Cost of products sold [Member] | Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net0 0 0 0
Cost of products sold [Member] | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net(5)(20)(63)(76)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax(17)(20)(69)(76)
Cost of products sold [Member] | Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net0 0
Cost of products sold [Member] | Forward Starting Interest Rate Swap Contracts [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net0 0
Cost of products sold [Member] | Deal Contingent Forward Starting Interest Rate Swap
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net0 0
Other (Income)/expense, net [Member] | Interest Rate Swap [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net(7)(6)(21)(18)
Other (Income)/expense, net [Member] | Cross Currency Interest Rate Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net(3)(2)(8)(6)
Other (Income)/expense, net [Member] | Foreign Exchange Forward [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net14 (9)(41)(11)
Other (Income)/expense, net [Member] | Foreign Exchange Contract [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net $ 0 $ 1
Other (Income)/expense, net [Member] | Forward Starting Interest Rate Swap Contracts [Member]
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net0 35
Other (Income)/expense, net [Member] | Deal Contingent Forward Starting Interest Rate Swap
Derivative [Line Items]
Derivative, Gain (Loss) on Derivative, Net $ 0 $ 240
London Interbank Offered Rate (LIBOR) [Member]
Derivative [Line Items]
Derivative, Variable Interest Rate0.15%0.15%0.15%

FINANCIAL INSTRUMENTS AND FAI_5

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Debt) (Details) - USD ($) $ in Millions3 Months Ended
Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019
Debt Instrument [Line Items]
Short-term Bank Loans and Notes Payable $ 183 $ 351
Current portion of long-term debt3,250 2,763
Other Short-term Borrowings152 232
Bank drafts and short-term borrowings3,585 3,346
Debt Instrument, Face Amount42,896 44,335
Adjustments to Principal Value, Unamortized basis adjustment from swap terminations155 175
Debt Instrument, Unamortized Discount(256)(280)
Debt Instrument, Unamortized Premium1,792 1,914
Total Debt44,614 46,150
Long-term debt41,364 43,387
Long-term debt, fair value52,700 50,700
Interest payments1,300 $ 166
Interest Rate Swap [Member]
Debt Instrument [Line Items]
Derivative Liability27 $ 6
1.600% Notes Due 2019 [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable $ 750
Interest rate on matured debt1.60%
1.750% Notes Due 2019 [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable $ 500
Interest rate on matured debt1.75%
$2.0 Billion Revolving Credit Facility Expiring in January 2020 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity2,000
$1.5 Billion Revolving Credit Facility Expiring in September 2023 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity1,500
$1.5 Billion Revolving Credit Facility Expiring in July 2024 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity1,500
19 Billion Senior Unsecured Notes [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount $ 19,000
2.875% Notes Due 2020 [Member]
Debt Instrument [Line Items]
Repayments of Notes Payable $ 1,500
Interest rate on matured debt2.875%
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity $ 6,000
Revolving Credit Facility [Member] | $1.0 Billion Revolving Credit Facility Expiring in January 2022 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Maximum Borrowing Capacity $ 1,000

RECEIVABLES (Details)

RECEIVABLES (Details) $ in Millions9 Months Ended
Sep. 30, 2020USD ($)Sep. 30, 2019USD ($)Dec. 31, 2019USD ($)
Account Receivables [Line Items]
Trade receivables $ 7,168 $ 6,888
Less charge-backs and cash discounts(371)(391)
Less allowances for expected credit loss(20)(21)
Net trade receivables6,777 6,476
Alliance, royalties, VAT and other1,285 1,209
Receivables8,062 $ 7,685
Non-U.S. receivables sold on a nonrecourse basis $ 788 $ 580
Number Of Largest Pharmaceutical Wholesalers3
Customer Concentration Risk [Member]
Account Receivables [Line Items]
Percent of aggregate total trade receivables due from three pharmaceutical wholesalers56.00%50.00%

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in MillionsSep. 30, 2020Dec. 31, 2019
Finished goods $ 822 $ 2,227
Work in process2,069 3,267
Raw and packaging materials221 172
Total inventories3,112 5,666
Inventories1,949 4,293
Inventories - other assets1,163 1,373
Inventory purchase price fair value adjustment [Member]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Inventory $ 883 $ 3,500

PROPERTY, PLANT AND EQUIPMENT_2

PROPERTY, PLANT AND EQUIPMENT (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Land $ 188 $ 188 $ 187
Buildings5,708 5,708 6,336
Machinery and equipment and fixtures3,101 3,101 3,157
Construction in progress409 409 527
Gross property, plant and equipment9,406 9,406 10,207
Less accumulated depreciation(3,666)(3,666)(3,955)
Property, plant and equipment5,740 5,740 $ 6,252
Depreciation expense $ 136 $ 135 $ 451 $ 401

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Goodwill $ 20,517 $ 20,517 $ 22,488
Gross other intangible assets68,069 68,069 68,106
Less: accumulated amortization(11,371)(11,371)(4,137)
Other intangible assets56,698 56,698 63,969
Acquired Developed Product Rights Reclassified From IPRD12,900
Amortization expense2,500 $ 52 7,300 $ 156
Licenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net461 461 482
Acquired developed product rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net59,651 59,651 46,827
Capitalized software [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Net1,357 1,357 1,297
In Process Research and Development [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
In-process research and development $ 6,600 $ 6,600 $ 19,500
Minimum [Member] | Licenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life5 years
Minimum [Member] | Acquired developed product rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life3 years
Minimum [Member] | Capitalized software [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life3 years
Maximum [Member] | Licenses [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life15 years
Maximum [Member] | Acquired developed product rights [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life15 years
Maximum [Member] | Capitalized software [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life10 years

SUPPLEMENTAL FINANCIAL INFORM_3

SUPPLEMENTAL FINANCIAL INFORMATION Other Current Assets (Details) - USD ($) $ in MillionsSep. 30, 2020Dec. 31, 2019
Other Current Assets [Abstract]
Prepaid and refundable income taxes $ 1,633 $ 754
Research and Development462 410
Equity investments126 0
Other890 819
Other current assets3,111 1,983
Restricted Cash425
Other current assets3,111 $ 1,983
Other Current Assets [Member]
Restricted Cash $ 84

SUPPLEMENTAL FINANCIAL INFORM_4

SUPPLEMENTAL FINANCIAL INFORMATION Other Non-Current Assets (Details) - USD ($) $ in MillionsSep. 30, 2020Dec. 31, 2019
Other Non-Current Assets [Abstract]
Equity investments $ 4,166 $ 3,405
Inventories1,163 1,373
Operating leases718 704
Pension and postretirement222 456
Restricted cash - non current341 390
Other286 276
Other non-current assets6,896 $ 6,604
Restricted Cash $ 425

SUPPLEMENTAL FINANCIAL INFORM_5

SUPPLEMENTAL FINANCIAL INFORMATION Other Current Liabilities (Details) - USD ($) $ in MillionsSep. 30, 2020Dec. 31, 2019
Other Liabilities, Current [Abstract]
Rebates and returns $ 5,747 $ 4,275
Income taxes payable686 1,517
Employee compensation and benefits1,069 1,457
Research and development1,315 1,324
Dividends1,043 1,025
Interest380 493
Royalties398 418
Operating leases136 133
Other1,984 1,871
Other current liabilities14,438 12,513
Other Current Liabilities [Member] | Contingent Value Rights [Member]
Contingent value rights $ 1,680 $ 0

SUPPLEMENTAL FINANCIAL INFORM_6

SUPPLEMENTAL FINANCIAL INFORMATION Other Non-Current Liabilities (Details) - USD ($) $ in MillionsSep. 30, 2020Dec. 31, 2019
Income taxes payable $ 5,025 $ 5,368
Pension and postretirement871 725
Operating leases722 672
Deferred Income361 424
Deferred compensation301 287
Other268 350
Other non-current liabilities7,565 10,101
Contingent Value Rights [Member] | Other Noncurrent Liabilities
Contingent value rights $ 17 $ 2,275

EQUITY (Changes in Equity) (Det

EQUITY (Changes in Equity) (Details) - USD ($) $ / shares in Units, shares in Millions, $ in MillionsJan. 01, 2019Sep. 30, 2020Jun. 30, 2020Mar. 31, 2020Sep. 30, 2019Jun. 30, 2019Mar. 31, 2019Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019
Common Stock, Dividends, Per Share, Declared $ 0.45 $ 0.45 $ 0.45 $ 0.41 $ 0.41 $ 0.41
Stock Repurchase Program, Remaining Authorized Repurchase Amount $ 5,900 $ 5,900 $ 1,000
Stock Repurchase Program, Authorized Amount5,000 5,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Value, Issued, Balance at Beginning of Period $ 292 292
Common Stock, Value, Issued, Balance at End of Period292 292
Capital in Excess of Par Value of Stock, Balance at Beginning of Period43,709 43,709
Capital in Excess of Par Value of Stock, Balance at End of Period44,435 44,435
Accumulated Other Comprehensive Loss, Balance at Beginning of Period(1,520)(1,520)
Other Comprehensive (Loss)/Income(143) $ 1,158 (179) $ 1,299
Accumulated Other Comprehensive Loss, Balance at End of Period(1,699)(1,699)
Retained Earnings, Balance at Beginning of Period $ 34,474 34,474
Net (Loss)/Earnings Attributable to BMS1,872 $ 1,353 1,012 4,495
Retained Earnings, Balance at End of Period $ 32,414 $ 32,414
Stock repurchase program, Shares0 16 1 6.5 1.4
Cost of Treasury Stock, Balance at Beginning of Period $ (25,357) $ (25,357)
Stock Repurchased During Period, Value(81) $ (300)(81)
Cost of Treasury Stock, Balance at End of Period $ (25,284)(25,284)
Noncontrolling interest $ 100 100
Noncontrolling Interest(6)(13)(20) $ (25)
Noncontrolling interest $ 72 $ 72
2019 ASR [Member]
Stock Repurchase Program, Authorized Amount $ 7,000
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock repurchase program, Shares16 99
Stock Repurchased During Period, Value $ 0 $ (1,400) $ (300)
Common Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Common Stock, Shares Issued, Balance at Beginning of Period2,208 2,923 2,923 2,923 2,208 2,208 2,208 2,923 2,208
Common Stock, Shares Issued, Balance at End of Period2,208 2,923 2,923 2,923 2,208 2,208 2,208 2,923 2,208
Common Stock, Value, Issued, Balance at Beginning of Period $ 221 $ 292 $ 292 $ 292 $ 221 $ 221 $ 221 $ 292 $ 221
Common Stock, Value, Issued, Balance at End of Period221 292 292 292 221 221 221 292 221
Capital in Excess of Par Value of Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Capital in Excess of Par Value of Stock, Balance at Beginning of Period2,081 44,444 43,254 43,709 2,150 2,103 2,081 43,709 2,081
Treasury Stock, Value, Acquired, Cost Method0 1,400
Stock compensation(9)(210)(455)56 47 22
Capital in Excess of Par Value of Stock, Balance at End of Period2,081 44,435 44,444 43,254 2,206 2,150 2,103 44,435 2,206
Accumulated Other Comprehensive Loss
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Accumulated Other Comprehensive Loss, Balance at Beginning of Period(2,762)(1,556)(1,549)(1,520)(2,621)(2,644)(2,762)(1,520)(2,762)
Other Comprehensive (Loss)/Income(143)(7)(29)1,158 23 118
Accumulated Other Comprehensive Loss, Balance at End of Period(2,762)(1,699)(1,556)(1,549)(1,463)(2,621)(2,644)(1,699)(1,463)
Retained Earnings [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Retained Earnings, Balance at Beginning of Period34,065 31,565 32,671 34,474 35,870 35,109 34,065 34,474 34,065
Net (Loss)/Earnings Attributable to BMS1,872 (85)(775)1,353 1,432 1,710
Cash dividends declared(1,023)(1,021)(1,028)(668)(671)(671)
Retained Earnings, Balance at End of Period $ 34,070 $ 32,414 $ 31,565 $ 32,671 $ 36,555 $ 35,870 $ 35,109 $ 32,414 $ 36,555
Treasury Stock [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Treasury Stock, Shares, Balance at Beginning of Period576 669 660 672 572 572 576 672 576
Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation(6)(7)(13)0 (4)
Treasury Stock, Shares, Balance at End of Period576 663 669 660 579 572 572 663 579
Cost of Treasury Stock, Balance at Beginning of Period $ (19,574) $ (25,651) $ (24,757) $ (25,357) $ (19,571) $ (19,571) $ (19,574) $ (25,357) $ (19,574)
Employee stock compensation plans, Cost367 506 681 0 3
Cost of Treasury Stock, Balance at End of Period(19,574)(25,284)(25,651)(24,757)(19,871)(19,571)(19,571)(25,284)(19,871)
Noncontrolling Interest [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Noncontrolling interest96 66 66 100 102 99 96 100 96
Noncontrolling Interest6 5 9 13 7 5
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders0 (5)(43)(9)(4)(2)
Noncontrolling interest96 $ 72 $ 66 $ 66 $ 106 $ 102 $ 99 $ 72 $ 106
Accounting Standards Update 2016-02 [Member]
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of an accounting change on retained earnings $ 5

EQUITY (Other Comprehensive Inc

EQUITY (Other Comprehensive Income/(Loss)) (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019Dec. 31, 2019
Other Comprehensive Income (Loss), before Tax [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax $ (128) $ 63 $ (65) $ 102
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax(17)(20)(69)(76)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax(145)43 (134)26
Pension and postretirement benefits - Actuarial gains/(losses), Pre-tax(16)(126)(28)(140)
Pension and postretirement benefits - Amortization, Pre-tax9 12 27 45
Pension and postretirement benefits - Curtailments and settlements, Pre-Tax3 1,550 7 1,643
Pension and postretirement benefits, Pre-tax(4)1,436 6 1,548
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments and Tax10 42
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax(1)3
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax(4)6 9 45
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax(16)10 (81)39
Other Comprehensive Income/(Loss), Pre-tax(169)1,495 (200)1,658
Other Comprehensive Income (Loss), Tax, Parenthetical Disclosures [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax10 (8)4 (12)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax3 3 9 10
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax13 (5)13 (2)
Pension and postretirement benefits - Actuarial gains/(losses), Tax3 27 6 30
Pension and postretirement benefits - Amortization, Tax(2)(2)(5)(8)
Pension and postretirement benefits - Curtailments and settlements, Tax(1)(345)(2)(366)
Pension and postretirement benefits, Tax0 (320)(1)(344)
Other Comprehensive Income (Loss), Available-for-sale Securities, before Reclassification Adjustments, Tax(2)(2)
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax0 0
Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax2 (2)(2)(2)
Foreign currency translation, Tax11 (10)11 (11)
Other comprehensive income/(loss), Tax26 (337)21 (359)
Other Comprehensive Income (Loss), Net of Tax [Abstract]
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax(118)55 (61)90
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax(14)(17)(60)(66)
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax(132)38 (121)24
Pension and postretirement benefits - Actuarial gains/(losses), After tax(13)(99)(22)(110)
Pension and postretirement benefits - Amortization, After tax7 10 22 37
Pension and postretirement benefits - Curtailments and settlements, After tax2 1,205 5 1,277
Pension and postretirement benefits, After tax(4)1,116 5 1,204
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Reclassification Adjustments, after Tax8 40
Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax(1)3
Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, after Tax(2)4 7 43
Foreign currency translation(5)0 (70)28
Other Comprehensive (Loss)/Income(143) $ 1,158 (179) $ 1,299
Derivatives qualifying as cash flow hedges(102)(102) $ 19
Pension and postretirement benefits(894)(894)(899)
Available-for-sale securities13 13 6
Foreign currency translation(716)(716)(646)
Accumulated other comprehensive loss $ (1,699) $ (1,699) $ (1,520)

PENSION AND POSTRETIREMENT BE_3

PENSION AND POSTRETIREMENT BENEFIT PLANS (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Jun. 30, 2020Dec. 31, 2019Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Net periodic benefit cost/(credit) $ 0 $ 1,537 $ (6) $ 1,607
Pension and postretirement871 $ 725 871
Defined contribution plan expense70 50 220 140
Pension Assets Transfer $ 381
Reversion excise tax0 $ 76 0 76 0
Payment for Pension Benefits200 1,300
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement1,500
Bristol-Myers Squibb Retirement Income Plan [Member]
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Defined Benefit Plan, Benefit Obligation2,400 2,400
Pension Benefits [Member]
Pension, Postretirement And Postemployment Liabilities Statement [Line Items]
Service cost - benefits earned during the period12 6 36 18
Interest cost on projected benefit obligation11 20 30 101
Expected return on plan assets(26)(39)(73)(173)
Amortization of prior service credits(1)(1)(3)(3)
Amortization of net actuarial (gain)/loss12 14 33 49
Curtailment and settlements3 1,550 7 1,643
Net periodic benefit cost/(credit)11 $ 1,550 30 $ 1,635
Pension and postretirement $ 588 $ 569 $ 588

EMPLOYEE STOCK BENEFIT PLANS Sh

EMPLOYEE STOCK BENEFIT PLANS Share-based Payment Arrangement, Cost by Plan (Details) - USD ($) $ in Millions3 Months Ended9 Months Ended
Sep. 30, 2020Sep. 30, 2019Sep. 30, 2020Sep. 30, 2019
Share-based Payment Arrangement, Expense $ 185 $ 56 $ 608 $ 157
Share-based Payment Arrangement, Expense, Tax Benefit38 10 124 29
Proceeds and Excess Tax Benefit from Share-based Compensation1 29
Cost of products sold [Member]
Share-based Payment Arrangement, Expense9 4 28 11
Marketing, selling and administrative [Member]
Share-based Payment Arrangement, Expense81 32 255 90
Research and development [Member]
Share-based Payment Arrangement, Expense78 20 261 56
Other (Income)/expense, net [Member]
Share-based Payment Arrangement, Expense17 $ 0 64 $ 0
Celgene [Member]
Share-based Payment Arrangement, Expense85 306
Share-based Payment Arrangement, Accelerated Cost $ 17 64
Celgene [Member] | Celgene Contingent Value Rights [Member]
Share-based Payment Arrangement, Expense $ 5

EMPLOYEE STOCK BENEFIT PLANS Sc

EMPLOYEE STOCK BENEFIT PLANS Schedule Of Share Based Compensation Additional Information (Details) shares in Millions3 Months Ended
Sep. 30, 2020$ / sharesshares
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares13
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 53.62
Market share units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares0.9
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 53.92
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares1.4
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares $ 55.61

EMPLOYEE STOCK BENEFIT PLANS _3

EMPLOYEE STOCK BENEFIT PLANS Share-based Payment Arrangement, Nonvested Award, Cost (Details) $ in Millions3 Months Ended
Sep. 30, 2020USD ($)
Share-based Payment Arrangement, Option [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 54
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition1 year 6 months
Restricted Stock Units (RSUs) [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 991
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition2 years 7 months 6 days
Market share units [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 53
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition3 years
Performance Shares [Member]
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount $ 93
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition1 year 9 months 18 days

LEGAL PROCEEDINGS AND CONTING_2

LEGAL PROCEEDINGS AND CONTINGENCIES (Details)3 Months Ended
Sep. 30, 2020USD ($)lawsuits
Anti-PD-1 Antibody Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number6
Eliquis Patent Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Patents Allegedly Infringed, Number2
Loss Contingency, Number of Plaintiffs25
Plavix Australia Intellectual Property [Member] | Australia, Dollars
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss $ 449,000,000
Plavix Australia Intellectual Property [Member] | United States of America, Dollars
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss $ 316,000,000
Abilify Product Liability [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number | lawsuits30
Byetta Product Liability Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number | lawsuits590
Securities Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss Contingency, Pending Claims, Number | lawsuits2
Cercla Matters [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss $ 76,600,000
Upfront, milestone and other licensing receipts [Member] | CAR T Kite Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss585,000,000
Royalty [Member] | CAR T Kite Litigation [Member]
Legal Proceedings And Contingencies [Line Items]
Loss contingency, Estimate of possible loss $ 0.276